

GenCore version 5.1.6
Copyright (c) 1993 - 2003 Comphen Ltd.

OM nucleic - nucleic search, using sw model

Run on: December 19, 2003, 12:58:44 ; Search time 48 Seconds
(without alignments)
193.105 Million cell updates/sec

Title: US-10-033-243-132

Sequence: 1 tcgtcgacgttcgatgat 21

Scoring table: OLIGO_NUC
Gapop 60.0, Gapext 60.0

Searched: 569978 seqs, 220691566 residues

Word size: 0

Total number of hits satisfying chosen parameters: 1139956

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-processing: Listing first 45 summaries

Database: Issued Patents NA:
1: /cgn2_6/prodata/2/ina/5A_COMB.seq:*
2: /cgn2_6/prodata/2/ina/5B_COMB.seq:*
3: /cgn2_6/prodata/2/ina/6A_COMB.seq:*
4: /cgn2_6/prodata/2/ina/6B_COMB.seq:*
5: /cgn2_6/prodata/2/ina/PCTUS_COMB.seq:*
6: /cgn2_6/prodata/2/ina/backfillseq.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	15	71.4	22	4	US-09-235-742-19
2	15	71.4	22	4	US-09-347-343-32
3	15	71.4	22	4	US-09-820-484-1
4	15	71.4	22	4	US-09-820-484-3
5	15	71.4	22	4	US-09-774-403A-1
6	14	66.7	816	3	US-08-776-251-10
7	14	66.7	816	3	US-08-776-251-10
8	14	66.7	4403765	3	US-09-103-840A-2
9	14	66.7	4411529	3	US-09-103-840A-1
10	13	61.9	321	3	US-09-060-756-260
11	13	61.9	321	3	US-09-240-274-197
12	13	61.9	321	4	US-09-570-314-260
13	13	61.9	462	4	US-09-252-991A-16046
14	13	61.9	573	4	US-09-252-991A-9162
15	13	61.9	663	4	US-09-252-991A-9246
16	13	61.9	762	4	US-09-252-991A-16554
17	13	61.9	813	4	US-09-107-532A-1566
18	13	61.9	1221	4	US-09-252-991A-8821
19	13	61.9	1461	4	US-09-252-991A-9074
20	13	61.9	1545	4	US-09-252-991A-8710
21	13	61.9	1986	4	US-09-252-991A-16328
22	13	61.9	2091	4	US-09-252-991A-15954
23	13	61.9	43804	4	US-09-171-461-1
24	12	57.1	20	3	US-09-286-098-11
25	12	57.1	20	4	US-09-325-193A-91
26	12	57.1	22	4	US-08-882-704A-18
27	12	57.1	22	2	US-08-882-704A-18

28	12	57.1	22	4	US-09-151-957-18	Sequence 18, Appl
29	12	57.1	22	4	US-09-151-957-18	Sequence 18, Appl
30	12	57.1	71	3	US-08-633-768A-12	Sequence 12, Appl
31	12	57.1	77	1	US-08-399-412A-58	Sequence 14, Appl
32	12	57.1	160	3	US-08-633-768A-14	Sequence 14, Appl
33	12	57.1	186	4	US-09-328-352-3855	Sequence 3855, Ap
34	12	57.1	212	4	US-09-313-294A-2448	Sequence 2448, Ap
35	12	57.1	268	4	US-09-313-294A-2857	Sequence 2857, Ap
36	12	57.1	283	4	US-09-313-294A-4896	Sequence 4896, Ap
37	12	57.1	288	4	US-09-252-991A-69	Sequence 69, Appl
38	12	57.1	378	4	US-09-252-991A-5259	Sequence 5259, Ap
39	12	57.1	406	3	US-09-060-756-563	Sequence 563, App
40	12	57.1	406	4	US-09-670-314-563	Sequence 563, App
41	12	57.1	432	4	US-09-252-991A-3530	Sequence 3530, Ap
42	12	57.1	441	4	US-09-252-991A-4565	Sequence 4565, Ap
43	12	57.1	658	3	US-08-861-774E-69	Sequence 69, Appl
44	12	57.1	806	4	US-09-198-119C-78	Sequence 78, Appl
45	12	57.1	813	4	US-09-107-532A-1566	Sequence 1566, Ap

ALIGNMENTS

```

RESULT 1
US-09-235-742-19
; Sequence 19, Application US/09235742
; Patent No. 6498148
; GENERAL INFORMATION:
; APPLICANT: Raz, Eyal
; TITLE OF INVENTION: Immunization-Free Methods for Treating
; TITLE OF INVENTION: Antigen-Stimulated Inflammation in a Mammalian Host and
; TITLE OF INVENTION: Shifting the Host's Antigen Immune Responsiveness to a Th1
; FILE REFERENCE: 6510-170CON4
; CURRENT APPLICATION NUMBER: US/09/235,742
; EARLIER FILING DATE: 1999-01-21
; EARLIER APPLICATION NUMBER: 08/927,120
; EARLIER FILING DATE: 1997-09-05
; EARLIER APPLICATION NUMBER: 08/593,554
; EARLIER FILING DATE: 1996-01-30
; EARLIER APPLICATION NUMBER: 08/725,968
; EARLIER FILING DATE: 1996-10-04
; EARLIER APPLICATION NUMBER: 60/028,118
; EARLIER FILING DATE: 1996-10-11
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 19
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Recombinant or Synthetic Sequence
US-09-235-742-19
Query Match          71.4%; Score 15; DB 4; Length 22;
Best Local Similarity 100.0%; Pred No. 2.1;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY      6 GAACGTTGAGATGA 20
      |||||
Db      8 GAACGTTGAGATGA 22
      |||||

RESULT 2
US-09-347-343-32
; Sequence 32, Application US/09347343A
; Patent No. 6514948
; GENERAL INFORMATION:
; APPLICANT: Raz, Eyal R.
; APPLICANT: KOBAYASHI, Hiroko
; TITLE OF INVENTION: METHOD FOR ENHANCING AN IMMUNE RESPONSE
; FILE REFERENCE: 30448.64US01
; CURRENT APPLICATION NUMBER: US/09/347,343A

```

```

; CURRENT FILING DATE: 1999-07-02
; NUMBER OF SEQ ID NOS: 40
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 32
; LENGTH: 22
; TYPE: DNA
; ORGANISM: synthetic oligonucleotide
US-09-347-343-32

Query Match      71.4%; Score 15; DB 4; Length 22;
Best Local Similarity 100.0%; Pred. No. 2.1;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      6 GAACGTCGAGATGA 20
      |||
      8 GAACGTCGAGATGA 22

Db

RESULT 3
US-09-820-484-1
; Sequence 1, Application US/09820484
; Patent No. 6534062
; GENERAL INFORMATION:
; APPLICANT: Raz, Eyal
; APPLICANT: Cho, Hearn Jay
; APPLICANT: Richman, Douglas
; APPLICANT: Horner, Anthony A.
; TITLE OF INVENTION: Method for Increasing a Cytotoxic T
; FILE REFERENCE: 06510-188US1
; CURRENT APPLICATION NUMBER: US/09/820,484
; CURRENT FILING DATE: 2001-03-28
; PRIOR APPLICATION NUMBER: US 60/192,537
; PRIOR FILING DATE: 2000-03-28
; PRIOR APPLICATION NUMBER: US 60/203,567
; PRIOR FILING DATE: 2000-05-11
; PRIOR APPLICATION NUMBER: US 60/215,995
; PRIOR FILING DATE: 2000-07-05
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Disulfide-linked phosphorothioate ISS-ODN
; NAME/KEY: modified base
; LOCATION: (1)...(1)
; OTHER INFORMATION: disulfide thymine
US-09-820-484-1

Query Match      71.4%; Score 15; DB 4; Length 22;
Best Local Similarity 100.0%; Pred. No. 2.1;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      6 GAACGTCGAGATGA 20
      |||
      8 GAACGTCGAGATGA 22

Db

RESULT 4
US-09-820-484-3
; Sequence 3, Application US/09820484
; Patent No. 6534062
; GENERAL INFORMATION:
; APPLICANT: Raz, Eyal
; APPLICANT: Cho, Hearn Jay
; APPLICANT: Richman, Douglas
; APPLICANT: Horner, Anthony A.
; TITLE OF INVENTION: Method for Increasing a Cytotoxic T
; FILE REFERENCE: 06510-188US1
; CURRENT APPLICATION NUMBER: US/09/820,484

; CURRENT FILING DATE: 2001-03-28
; PRIOR APPLICATION NUMBER: US 60/192,537
; PRIOR FILING DATE: 2000-03-28
; PRIOR APPLICATION NUMBER: US 60/203,567
; PRIOR FILING DATE: 2000-05-11
; PRIOR APPLICATION NUMBER: US 60/215,995
; PRIOR FILING DATE: 2000-07-05
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: phosphorothioate ISS-ODN
US-09-820-484-3

Query Match      71.4%; Score 15; DB 4; Length 22;
Best Local Similarity 100.0%; Pred. No. 2.1;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      6 GAACGTCGAGATGA 20
      |||
      8 GAACGTCGAGATGA 22

Db

RESULT 5
US-09-774-403A-1
; Sequence 1, Application US/09774403A
; Patent No. 6552006
; GENERAL INFORMATION:
; APPLICANT: Eyal Raz
; APPLICANT: Richard Kornbluth
; APPLICANT: Antonio Catanzaro
; APPLICANT: Tomoko Hayashi
; APPLICANT: Dennis Carson
; TITLE OF INVENTION: Immunomodulatory Polynucleotides in
; FILE REFERENCE: UCAL166
; CURRENT APPLICATION NUMBER: US/09/774,403A
; CURRENT FILING DATE: 2002-04-15
; PRIOR APPLICATION NUMBER: 60/179,353
; PRIOR FILING DATE: 2000-01-31
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Immunomodulatory sequence
US-09-774-403A-1

Query Match      71.4%; Score 15; DB 4; Length 22;
Best Local Similarity 100.0%; Pred. No. 2.1;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      6 GAACGTCGAGATGA 20
      |||
      8 GAACGTCGAGATGA 22

Db

RESULT 6
US-08-776-251-10
; Sequence 10, Application US/08776251
; Patent No. 6025340
; GENERAL INFORMATION:
; APPLICANT: Springer, Caroline J
; APPLICANT: Matsis, Richard
; TITLE OF INVENTION: Surface expression of enzyme in gene directed prodrug therapy
; NUMBER OF SEQUENCES: 27
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Nixon & Vanderhye
```

STREET: 1100 No. 6025340th Glebe Road, 8th Floor
CITY: Arlington
STATE: Virginia
COUNTRY: USA
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/776,251.
FILING DATE: 31-JAN-1997
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/GB95/01782
FILING DATE: 27-JUL-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9415167.7
FILING DATE: 27-JUL-1994
ATTORNEY/AGENT INFORMATION:
NAME: Arthur R. Crawford
REGISTRATION NUMBER: 25,327
REFERENCE/DOCKET NUMBER: 620-20
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 816 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
US-08-776-251-10

Query Match 66.7%; Score 14; DB 3; Length 816;
Best Local Similarity 100.0%; Pred. No. 6.5;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 TCGAACGTTTCGAGA 17
Db 619 TCGAACGTTTCGAGA 632

RESULT 7
US-08-776-251-10/c
Sequence 10, Application US/08776251
Patent No. 6025340
GENERAL INFORMATION:
APPLICANT: Springer, Caroline J
APPLICANT: Marais, Richard
TITLE OF INVENTION: Surface expression of enzyme in gene directed prodng therapy
NUMBER OF SEQUENCES: 27
CORRESPONDENCE ADDRESS:
ADDRESSEE: Nixon & Vanderhye
STREET: 1100 No. 6025340th Glebe Road, 8th Floor
CITY: Arlington
STATE: Virginia
COUNTRY: USA
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/776,251
FILING DATE: 31-JAN-1997
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/GB95/01782
FILING DATE: 27-JUL-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9415167.7
FILING DATE: 27-JUL-1994
ATTORNEY/AGENT INFORMATION:
NAME: Arthur R. Crawford
REGISTRATION NUMBER: 25,327
REFERENCE/DOCKET NUMBER: 620-20

INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 816 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
US-08-776-251-10

Query Match 66.7%; Score 14; DB 3; Length 816;
Best Local Similarity 100.0%; Pred. No. 6.5;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 TCGAACGTTTCGAGA 17
Db 801 TCGAACGTTTCGAGA 788

RESULT 8
US-09-103-840A-2/c
Sequence 2, Application US/09103840A
Patent No. 6294328
GENERAL INFORMATION:
APPLICANT: FLEISCHMAN, Robert D.
APPLICANT: WHITE, Owen R.
APPLICANT: FRASER, Claire M.
APPLICANT: VENTER, John C.
TITLE OF INVENTION: DNA SEQUENCES FOR STRAIN ANALYSIS IN MYCOBACTERIUM
FILE REFERENCE: 24366-20007.00
CURRENT APPLICATION NUMBER: US/09/103,840A
CURRENT FILING DATE: 1998-06-24
NUMBER OF SEQ ID NOS: 2
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 2
LENGTH: 4403765
TYPE: DNA
ORGANISM: Mycobacterium tuberculosis
FEATURE:
OTHER INFORMATION: CDC 1551
OTHER INFORMATION: "n" bases at various positions throughout the sequence
OTHER INFORMATION: represent a, t, c or g
US-09-103-840A-2

Query Match 66.7%; Score 14; DB 3; Length 4403765;
Best Local Similarity 100.0%; Pred. No. 3.8;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TCGTCGAACGTTTCG 14
Db 735047 TCGTCGAACGTTTCG 735034

RESULT 9
US-09-103-840A-1/c
Sequence 1, Application US/09103840A
Patent No. 6294328
GENERAL INFORMATION:
APPLICANT: FLEISCHMAN, Robert D.
APPLICANT: WHITE, Owen R.
APPLICANT: FRASER, Claire M.
APPLICANT: VENTER, John C.
TITLE OF INVENTION: DNA SEQUENCES FOR STRAIN ANALYSIS IN MYCOBACTERIUM
FILE REFERENCE: 24366-20007.00
CURRENT APPLICATION NUMBER: US/09/103,840A
CURRENT FILING DATE: 1998-06-24
NUMBER OF SEQ ID NOS: 2
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 1
LENGTH: 4411529
TYPE: DNA
ORGANISM: Mycobacterium tuberculosis

OTHER INFORMATION: H37Rv
US-09-103-840A-1

Query Match 66.7%; Score 14; DB 3; Length 4411529;
Best Local Similarity 100.0%; Pred. No. 3.8;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TCGTCGACGTCG 14
Db 733615 TCGTCGACGTCG 733602

RESULT 10
US-09-060-756-260

; Sequence 260, Application US/09060756
; Patent No. 6183957
; GENERAL INFORMATION:
; APPLICANT: Cole, Stewart
; APPLICANT: Buchrieser-Brosch, Roland
; APPLICANT: Gordon, Stephen
; APPLICANT: Billault, Alain
; TITLE OF INVENTION: METHOD FOR ISOLATING A POLYNUCLEOTIDE OF INTEREST FROM
; TITLE OF INVENTION: THE GENOME OF A MYCOBACTERIUM USING A BAC-BASED DNA
; FILE REFERENCE: 3495-0169
; CURRENT APPLICATION NUMBER: US/09/060,756
; CURRENT FILING DATE: 1998-04-16
; NUMBER OF SEQ ID NOS: 743
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 260
; LENGTH: 321
; TYPE: DNA
; ORGANISM: Mycobacterium tuberculosis
; FEATURE:
; NAME/KEY: unsure
; LOCATION: (various positions within the sequence)
; OTHER INFORMATION: applicants are uncertain of bases designated as "n"
US-09-060-756-260

Query Match 61.9%; Score 13; DB 3; Length 321;
Best Local Similarity 100.0%; Pred. No. 27;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 ACGTTCGAGTGA 20
Db 75 ACGTTCGAGTGA 87

RESULT 11

US-09-240-274-197/c
; Sequence 197, Application US/09240274
; Patent No. 6255455
; GENERAL INFORMATION:
; APPLICANT: Siegel, Donald L.
; TITLE OF INVENTION: RH(D)-BINDING PROTEINS AND MAGNETICALLY ACTIVATED CELL
; TITLE OF INVENTION: SORTING METHOD FOR PRODUCTION THEREOF
; FILE REFERENCE: 09596-4202
; CURRENT APPLICATION NUMBER: US/09/240,274
; CURRENT FILING DATE: 1999-01-29
; EARLIER APPLICATION NUMBER: 60/081,380
; EARLIER FILING DATE: 1998-04-10
; EARLIER APPLICATION NUMBER: 60/028,550
; EARLIER FILING DATE: 1996-10-11
; NUMBER OF SEQ ID NOS: 224
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 197
; LENGTH: 321
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: anti-Rh(D) antibody clone SH8
US-09-240-274-197

Query Match 61.9%; Score 13; DB 3; Length 321;
Best Local Similarity 100.0%; Pred. No. 27;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5 CGAAGTTCGAGA 17
Db 292 CGAAGTTCGAGA 280

RESULT 12
US-09-670-314-260

; Sequence 260, Application US/09670314
; Patent No. 6492506
; GENERAL INFORMATION:
; APPLICANT: Cole, Stewart
; APPLICANT: Buchrieser-Brosch, Roland
; APPLICANT: Gordon, Stephen
; APPLICANT: Billault, Alain
; TITLE OF INVENTION: METHOD FOR ISOLATING A POLYNUCLEOTIDE OF INTEREST FROM
; TITLE OF INVENTION: THE GENOME OF A MYCOBACTERIUM USING A BAC-BASED DNA
; FILE REFERENCE: 3495-0169
; CURRENT APPLICATION NUMBER: US/09/670,314
; CURRENT FILING DATE: 2001-01-12
; PRIOR APPLICATION NUMBER: 09/060,756
; PRIOR FILING DATE: 1998-04-16
; NUMBER OF SEQ ID NOS: 743
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 260
; LENGTH: 321
; TYPE: DNA
; ORGANISM: Mycobacterium tuberculosis
; FEATURE:
; NAME/KEY: unsure
; LOCATION: (various positions within the sequence)
; OTHER INFORMATION: applicants are uncertain of bases designated as "n"
US-09-670-314-260

Query Match 61.9%; Score 13; DB 4; Length 321;
Best Local Similarity 100.0%; Pred. No. 27;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 ACGTTCGAGTGA 20
Db 75 ACGTTCGAGTGA 87

RESULT 13

US-09-252-991A-16046
; Sequence 16046, Application US/09252991A
; Patent No. 6551795
; GENERAL INFORMATION:
; APPLICANT: Marc J. Rubenfield et al.
; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO PSEUDOMONAS
; TITLE OF INVENTION: AERUGINOSA FOR DIAGNOSTICS AND THERAPEUTICS
; FILE REFERENCE: 107196-136
; CURRENT APPLICATION NUMBER: US/09/252,991A
; CURRENT FILING DATE: 1999-02-18
; PRIOR APPLICATION NUMBER: US 60/074,788
; PRIOR FILING DATE: 1998-02-18
; PRIOR APPLICATION NUMBER: US 60/094,190
; PRIOR FILING DATE: 1998-07-27
; NUMBER OF SEQ ID NOS: 33142
; SEQ ID NO 16046
; LENGTH: 462
; TYPE: DNA
; ORGANISM: Pseudomonas aeruginosa
US-09-252-991A-16046

Query Match 61.9%; Score 13; DB 4; Length 462;
Best Local Similarity 100.0%; Pred. No. 27;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 8 ACCTTCGAGATGA 20
 |||||
 Db 34 ACCTTCGAGATGA 46

RESULT 14

US-09-252-991A-9162/C
 ; Sequence 9162, Application US/09252991A
 ; Patent No. 6551795
 ; GENERAL INFORMATION:
 ; APPLICANT: Marc J. Rubenfield et al.
 ; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO PSEUDOMONAS
 ; FILE REFERENCE: 107196.136
 ; CURRENT APPLICATION NUMBER: US/09/252,991A
 ; PRIOR FILING DATE: 1999-02-18
 ; PRIOR APPLICATION NUMBER: US 60/074,788
 ; PRIOR FILING DATE: 1998-02-18
 ; PRIOR APPLICATION NUMBER: US 60/094,190
 ; NUMBER OF SEQ ID NOS: 33142
 ; SEQ ID NO 9162
 ; LENGTH: 573
 ; TYPE: DNA
 ; ORGANISM: Pseudomonas aeruginosa
 ; FEATURE:
 ; NAME/KEY: unsure
 ; LOCATION: (17)
 ; OTHER INFORMATION: Identity of nucleotide at the above locations are unknown.
 US-09-252-991A-9162

Query Match 61.9%; Score 13; DB 4; Length 573;
 Best Local Similarity 100.0%; Pred. No. 26;

Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 6 GAACGTTGAGAT 18
 |||||
 Db 286 GAACGTTGAGAT 274

RESULT 15

US-09-252-991A-9246/C
 ; Sequence 9246, Application US/09252991A
 ; Patent No. 6551795
 ; GENERAL INFORMATION:
 ; APPLICANT: Marc J. Rubenfield et al.
 ; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO PSEUDOMONAS
 ; FILE REFERENCE: 107196.136
 ; CURRENT APPLICATION NUMBER: US/09/252,991A
 ; PRIOR FILING DATE: 1999-02-18
 ; PRIOR APPLICATION NUMBER: US 60/074,788
 ; PRIOR FILING DATE: 1998-02-18
 ; PRIOR APPLICATION NUMBER: US 60/094,190
 ; NUMBER OF SEQ ID NOS: 33142
 ; SEQ ID NO 9246
 ; LENGTH: 663
 ; TYPE: DNA
 ; ORGANISM: Pseudomonas aeruginosa
 US-09-252-991A-9246

Query Match 61.9%; Score 13; DB 4; Length 663;
 Best Local Similarity 100.0%; Pred. No. 26;

Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 6 GAACGTTGAGAT 18
 |||||
 Db 45 GAACGTTGAGAT 33

Search completed: December 19, 2003, 13:47:04
 Job time : 61 secs

This Page Blank (uspto)


```
APPLICANT: Van Nest, Gary
APPLICANT: Tuck, Stephen L.
APPLICANT: Fearon, Karen L.
APPLICANT: Dina, Dino
TITLE OF INVENTION: BIODEGRADABLE IMMUNOMODULATORY
TITLE OF INVENTION: FORMULATIONS AND METHODS FOR USE THEREOF
FILE REFERENCE: 377882001420
CURRENT APPLICATION NUMBER: US/09/927,422A
CURRENT FILING DATE: 2001-08-10
PRIOR APPLICATION NUMBER: U.S. 09/802,359
PRIOR FILING DATE: 2001-03-09
PRIOR APPLICATION NUMBER: U.S. 60/188,30
PRIOR FILING DATE: 2000-03-10
NUMBER OF SEQ ID NOS: 23
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 16
LENGTH: 19
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Polynucleotide containing CG
US-09-927-422A-16
```

```
Query Match          90.5%; Score 19; DB 11; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.065;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1 TCGTCGAACGTTGCAGATG 19
        |||||
Db      1 TCGTCGAACGTTGCAGATG 19
```

```
RESULT 3
US-10-176-883-41
; Sequence 41, Application US/10176883
; Publication No. US20030175731A1
; GENERAL INFORMATION:
; APPLICANT: Fearon, Karen
; APPLICANT: Dina, Dino
; APPLICANT: Tuck, Stephen
; TITLE OF INVENTION: CHIMERIC IMMUNOMODULATORY COMPOUNDS AND
; TITLE OF INVENTION: METHODS OF USING THE SAME-I
; FILE REFERENCE: 377882002000
; CURRENT APPLICATION NUMBER: US/10/176,883
; CURRENT FILING DATE: 2002-06-21
; PRIOR APPLICATION NUMBER: 60/239,883
; PRIOR FILING DATE: 2001-06-21
; PRIOR APPLICATION NUMBER: 60/375,253
; PRIOR FILING DATE: 2002-04-23
; NUMBER OF SEQ ID NOS: 141
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 41
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic construct
US-10-176-883-41
```

```
Query Match          90.5%; Score 19; DB 13; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.065;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1 TCGTCGAACGTTGCAGATG 19
        |||||
Db      1 TCGTCGAACGTTGCAGATG 19
```

```
RESULT 4
US-10-177-826-41
; Sequence 41, Application US/10177826
; Publication No. US20030199466A1
; GENERAL INFORMATION:
```

```
APPLICANT: Fearon, Karen
APPLICANT: Dina, Dino
APPLICANT: Tuck, Stephen
APPLICANT: Dina, Dino
TITLE OF INVENTION: CHIMERIC IMMUNOMODULATORY COMPOUNDS AND
TITLE OF INVENTION: METHODS OF USING THE SAME-II
FILE REFERENCE: 377882002001
CURRENT APPLICATION NUMBER: US/10/177,826
CURRENT FILING DATE: 2002-06-21
PRIOR APPLICATION NUMBER: 60/239,883
PRIOR FILING DATE: 2001-06-21
PRIOR APPLICATION NUMBER: 60/375,253
PRIOR FILING DATE: 2002-04-23
NUMBER OF SEQ ID NOS: 141
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 41
LENGTH: 19
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic construct
US-10-177-826-41
```

```
Query Match          90.5%; Score 19; DB 13; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.065;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1 TCGTCGAACGTTGCAGATG 19
        |||||
Db      1 TCGTCGAACGTTGCAGATG 19
```

```
RESULT 5
US-10-033-243-19
; Sequence 19, Application US/10033243
; Publication No. US20030049266A1
; GENERAL INFORMATION:
; APPLICANT: FEARON, Karen L.
; APPLICANT: DINA, Dino
; TITLE OF INVENTION: IMMUNOMODULATORY POLYNUCLEOTIDES AND
; TITLE OF INVENTION: METHODS OF USING THE SAME
; FILE REFERENCE: 377882001800
; CURRENT APPLICATION NUMBER: US/10/033,243
; CURRENT FILING DATE: 2002-04-03
; PRIOR APPLICATION NUMBER: 60/258,675
; PRIOR FILING DATE: 2000-12-27
; NUMBER OF SEQ ID NOS: 133
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 19
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Polynucleotide containing CG
US-10-033-243-19
```

```
Query Match          90.5%; Score 19; DB 15; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.065;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1 TCGTCGAACGTTGCAGATG 19
        |||||
Db      1 TCGTCGAACGTTGCAGATG 19
```

```
RESULT 6
US-10-176-883-52
; Sequence 52, Application US/10176883
; Publication No. US20030175731A1
; GENERAL INFORMATION:
; APPLICANT: Fearon, Karen
; APPLICANT: Dina, Dino
; APPLICANT: Tuck, Stephen
; TITLE OF INVENTION: CHIMERIC IMMUNOMODULATORY COMPOUNDS AND
```


TITLE OF INVENTION: METHODS OF USING THE SAME-I
FILE REFERENCE: 377882002000
CURRENT APPLICATION NUMBER: US/10/176,883
CURRENT FILING DATE: 2002-06-21
PRIOR APPLICATION NUMBER: 60/299,883
PRIOR FILING DATE: 2001-06-21
PRIOR APPLICATION NUMBER: 60/375,253
PRIOR FILING DATE: 2002-04-23
NUMBER OF SEQ ID NOS: 141
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 52
LENGTH: 22
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic construct
US-10-176-883-52

Query Match 90.5%; Score 19; DB 13; Length 22;
Best Local Similarity 100.0%; Pred. No. 0.064;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TCGTCGACGTTGAGATG 19
DB 4 TCGTCGACGTTGAGATG 22

RESULT 7

US-10-177-826-52
Sequence 52, Application US/10177826
Publication No. US20030199466A1
GENERAL INFORMATION:
APPLICANT: Fearon, Karen
APPLICANT: Dina, Dino
TITLE OF INVENTION: CHIMERIC IMMUNOMODULATORY COMPOUNDS AND
TITLE OF INVENTION: METHODS OF USING THE SAME-II
FILE REFERENCE: 377882002001
CURRENT APPLICATION NUMBER: US/10/177,826
CURRENT FILING DATE: 2002-06-21
PRIOR APPLICATION NUMBER: 60/299,883
PRIOR FILING DATE: 2001-06-21
PRIOR APPLICATION NUMBER: 60/375,253
PRIOR FILING DATE: 2002-04-23
NUMBER OF SEQ ID NOS: 141
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 52
LENGTH: 22
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic construct
US-10-177-826-52

Query Match 90.5%; Score 19; DB 13; Length 22;
Best Local Similarity 100.0%; Pred. No. 0.064;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TCGTCGACGTTGAGATG 19
DB 4 TCGTCGACGTTGAGATG 22

RESULT 8

US-10-033-243-30
Sequence 30, Application US/10033243
Publication No. US20030049266A1
GENERAL INFORMATION:
APPLICANT: Fearon, Karen L.
APPLICANT: Dina, Dino
TITLE OF INVENTION: IMMUNOMODULATORY POLYNUCLEOTIDES AND
TITLE OF INVENTION: METHODS OF USING THE SAME
FILE REFERENCE: 377882001800

CURRENT APPLICATION NUMBER: US/10/033,243
CURRENT FILING DATE: 2002-04-03
PRIOR APPLICATION NUMBER: 60/258,675
PRIOR FILING DATE: 2000-12-27
NUMBER OF SEQ ID NOS: 133
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 30
LENGTH: 22
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Polynucleotide containing CG
US-10-033-243-30

Query Match 90.5%; Score 19; DB 15; Length 22;
Best Local Similarity 100.0%; Pred. No. 0.064;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TCGTCGACGTTGAGATG 19
DB 4 TCGTCGACGTTGAGATG 22

RESULT 9

US-10-176-883-36
Sequence 36, Application US/10176883
Publication No. US20030175731A1
GENERAL INFORMATION:
APPLICANT: Fearon, Karen
APPLICANT: Dina, Dino
TITLE OF INVENTION: CHIMERIC IMMUNOMODULATORY COMPOUNDS AND
TITLE OF INVENTION: METHODS OF USING THE SAME-I
FILE REFERENCE: 377882002000
CURRENT APPLICATION NUMBER: US/10/176,883
CURRENT FILING DATE: 2002-06-21
PRIOR APPLICATION NUMBER: 60/299,883
PRIOR FILING DATE: 2001-06-21
PRIOR APPLICATION NUMBER: 60/375,253
PRIOR FILING DATE: 2002-04-23
NUMBER OF SEQ ID NOS: 141
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 36
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic construct
US-10-176-883-36

Query Match 76.2%; Score 16; DB 13; Length 18;
Best Local Similarity 100.0%; Pred. No. 4.1;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4 TCGACGTTGAGATG 19
DB 3 TCGACGTTGAGATG 18

RESULT 10

US-10-177-826-36
Sequence 36, Application US/10177826
Publication No. US20030199466A1
GENERAL INFORMATION:
APPLICANT: Fearon, Karen
APPLICANT: Dina, Dino
TITLE OF INVENTION: CHIMERIC IMMUNOMODULATORY COMPOUNDS AND
TITLE OF INVENTION: METHODS OF USING THE SAME-II
FILE REFERENCE: 377882002001
CURRENT APPLICATION NUMBER: US/10/177,826
CURRENT FILING DATE: 2002-06-21
PRIOR APPLICATION NUMBER: 60/299,883

;; PRIOR FILING DATE: 2001-06-21
;; PRIOR APPLICATION NUMBER: 60/375,253
;; PRIOR FILING DATE: 2002-04-23
;; NUMBER OF SEQ ID NOS: 141
;; SOFTWARE: FastSeq for Windows Version 4.0
;; SEQ ID NO 36
;; LENGTH: 18
;; TYPE: DNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Synthetic construct
US-10-177-826-36

Query Match 76.2%; Score 16; DB 13; Length 18;
Best Local Similarity 100.0%; Pred. No. 4.1;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4 TCGAACGTCGAGATG 19
DB 3 TCGAACGTCGAGATG 18

RESULT 11
; Sequence 14, Application US/10033243
; Publication No. US20030049266A1
; GENERAL INFORMATION:
; APPLICANT: FEARON, Karen L.
; APPLICANT: DINA, Dino
; TITLE OF INVENTION: IMMUNOMODULATORY POLYNUCLEOTIDES AND
; TITLE OF INVENTION: METHODS OF USING THE SAME
; FILE REFERENCE: 377882001800
; CURRENT APPLICATION NUMBER: US/10/033,243
; CURRENT FILING DATE: 2002-04-03
; PRIOR APPLICATION NUMBER: 60/258,675
; PRIOR FILING DATE: 2000-12-27
; NUMBER OF SEQ ID NOS: 133
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 14
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Polynucleotide containing CG
US-10-033-243-14

Query Match 76.2%; Score 16; DB 15; Length 18;
Best Local Similarity 100.0%; Pred. No. 4.1;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4 TCGAACGTCGAGATG 19
DB 3 TCGAACGTCGAGATG 18

RESULT 12
; Sequence 139, Application US/10176883
; Publication No. US20030175731A1
; GENERAL INFORMATION:
; APPLICANT: Fearon, Karen
; APPLICANT: Dina, Dino
; APPLICANT: Tuck, Stephen
; TITLE OF INVENTION: CHIMERIC IMMUNOMODULATORY COMPOUNDS AND
; TITLE OF INVENTION: METHODS OF USING THE SAME-1
; FILE REFERENCE: 377882002000
; CURRENT APPLICATION NUMBER: US/10/176,883
; CURRENT FILING DATE: 2002-06-21
; PRIOR APPLICATION NUMBER: 60/299,883
; PRIOR FILING DATE: 2001-06-21
; PRIOR APPLICATION NUMBER: 60/375,253
; PRIOR FILING DATE: 2002-04-23
; NUMBER OF SEQ ID NOS: 141

;; SOFTWARE: FastSeq for Windows Version 4.0
;; SEQ ID NO 139
;; LENGTH: 66
;; TYPE: DNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Synthetic construct
US-10-176-883-139

Query Match 76.2%; Score 16; DB 13; Length 66;
Best Local Similarity 100.0%; Pred. No. 3.7;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 6 GAAAGTTGAGATGAT 21
DB 8 GAAAGTTGAGATGAT 23

RESULT 13
; Sequence 139, Application US/10177826
; Publication No. US20030199466A1
; GENERAL INFORMATION:
; APPLICANT: Fearon, Karen
; APPLICANT: Dina, Dino
; APPLICANT: Tuck, Stephen
; TITLE OF INVENTION: CHIMERIC IMMUNOMODULATORY COMPOUNDS AND
; TITLE OF INVENTION: METHODS OF USING THE SAME-11
; FILE REFERENCE: 377882002001
; CURRENT APPLICATION NUMBER: US/10/177,826
; CURRENT FILING DATE: 2002-06-21, 883
; PRIOR APPLICATION NUMBER: 60/299,883
; PRIOR FILING DATE: 2001-06-21
; PRIOR APPLICATION NUMBER: 60/375,253
; PRIOR FILING DATE: 2002-04-23
; NUMBER OF SEQ ID NOS: 141
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 139
; LENGTH: 66
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic construct
US-10-177-826-139

Query Match 76.2%; Score 16; DB 13; Length 66;
Best Local Similarity 100.0%; Pred. No. 3.7;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 6 GAAAGTTGAGATGAT 21
DB 8 GAAAGTTGAGATGAT 23

RESULT 14
; Sequence 21, Application US/09848986
; Publication No. US20030176373A1
; GENERAL INFORMATION:
; APPLICANT: Raz, Eyal
; APPLICANT: Lois, Augusto F.
; APPLICANT: Takabayashi, Kenji
; TITLE OF INVENTION: Agents that Modulate DNA-PK Activity and
; TITLE OF INVENTION: Methods of Use Thereof
; FILE REFERENCE: 06510168US1
; CURRENT APPLICATION NUMBER: US/09/848,986
; CURRENT FILING DATE: 2001-05-03
; PRIOR APPLICATION NUMBER: us 60/262321
; PRIOR FILING DATE: 2001-01-17
; PRIOR APPLICATION NUMBER: us 60/202,274
; PRIOR FILING DATE: 2000-05-05
; NUMBER OF SEQ ID NOS: 21
; SOFTWARE: FastSeq for Windows Version 4.0

```

; SEQ ID NO 21
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: ISS-ODN
US-09-848-986-21

```

```

Query Match      71.4%; Score 15; DB 13; Length 20;
Best Local Similarity 100.0%; Pred. No. 16;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY      6 GAACGTTGAGATGA 20
        |||||
        6 GAACGTTGAGATGA 20

```

```

RESULT 15
US-10-233-121A-21
; Sequence 21, Application US/10233121A
; Publication No. US20030125284A1
; GENERAL INFORMATION:
; APPLICANT: RAZ, EYAL
; APPLICANT: LOIS, AUGUSTO
; APPLICANT: TAKABAYASHI, KENDI
; TITLE OF INVENTION: AGENTS THAT MODULATE DNA-PK ACTIVITY AND
; TITLE OF INVENTION: METHODS OF USE THEREOF
; FILE REFERENCE: UCAL-168DIV
; CURRENT APPLICATION NUMBER: US/10/233,121A
; CURRENT FILING DATE: 2003-03-11
; PRIOR APPLICATION NUMBER: US 09/848,986
; PRIOR FILING DATE: 2001-05-04
; PRIOR APPLICATION NUMBER: US 60/202,274
; PRIOR FILING DATE: 2000-05-05
; PRIOR APPLICATION NUMBER: US 60/262,321
; PRIOR FILING DATE: 2001-01-17
; NUMBER OF SEQ ID NOS: 21
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 21
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: phosphodiester or phosphorothioate oligonucleotide
US-10-233-121A-21

```

```

Query Match      71.4%; Score 15; DB 15; Length 20;
Best Local Similarity 100.0%; Pred. No. 16;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY      6 GAACGTTGAGATGA 20
        |||||
        6 GAACGTTGAGATGA 20

```

Search completed: December 19, 2003, 13:43:23
Job time : 151 secs

This Page Blank (uspio)

GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: December 19, 2003, 12:58:44 / Search time 1308 Seconds
(without alignments)
390.209 Million cell updates/sec

Title: US-10-033-243-132

Perfect score: 21

Sequence: 1 tcgtcgaacgttcgagatgatc 21

Scoring table: OLIGO_NUC

Gapop 60.0 , Gapext 60.0

Searched: 22781392 seqs, 12152238056 residues

Word size: 0

Total number of hits satisfying chosen parameters: 45562784

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Listing first 45 summaries

Database:

EST:
1: em_estba:*
2: em_esthum:*
3: em_estin:*
4: em_estmu:*
5: em_estov:*
6: em_estpl:*
7: em_estro:*
8: em_hic:*
9: gb_est1:*
10: gb_est2:*
11: gb_hic:*
12: gb_est3:*
13: gb_est4:*
14: gb_est5:*
15: em_estfun:*
16: em_estom:*
17: em_gse_hum:*
18: em_gse_inv:*
19: em_gse_pin:*
20: em_gse_vrt:*
21: em_gse_fun:*
22: em_gse_nam:*
23: em_gse_mus:*
24: em_gse_pro:*
25: em_gse_rtd:*
26: em_gse_pmg:*
27: em_gse_vrl:*
28: gb_gse1:*
29: gb_gse2:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Length	ID	Description
C 1	15	71.4	194	BU095678 tca-163 t
C 2	15	71.4	337	BU095678 tca-163 t
C 3	15	71.4	390	BU095678 tca-163 t
C 4	15	71.4	432	BU095678 tca-163 t
C 5	15	71.4	432	BU095678 tca-163 t
C 6	15	71.4	432	BU095678 tca-163 t
C 7	15	71.4	432	BU095678 tca-163 t
C 8	15	71.4	432	BU095678 tca-163 t
C 9	15	71.4	432	BU095678 tca-163 t
C 10	15	71.4	432	BU095678 tca-163 t
C 11	15	71.4	432	BU095678 tca-163 t
C 12	15	71.4	432	BU095678 tca-163 t
C 13	15	71.4	432	BU095678 tca-163 t
C 14	15	71.4	432	BU095678 tca-163 t
C 15	15	71.4	432	BU095678 tca-163 t
C 16	15	71.4	432	BU095678 tca-163 t
C 17	15	71.4	432	BU095678 tca-163 t
C 18	15	71.4	432	BU095678 tca-163 t
C 19	15	71.4	432	BU095678 tca-163 t
C 20	15	71.4	432	BU095678 tca-163 t
C 21	15	71.4	432	BU095678 tca-163 t
C 22	15	71.4	432	BU095678 tca-163 t
C 23	15	71.4	432	BU095678 tca-163 t
C 24	15	71.4	432	BU095678 tca-163 t
C 25	15	71.4	432	BU095678 tca-163 t
C 26	15	71.4	432	BU095678 tca-163 t
C 27	15	71.4	432	BU095678 tca-163 t
C 28	15	71.4	432	BU095678 tca-163 t
C 29	15	71.4	432	BU095678 tca-163 t
C 30	15	71.4	432	BU095678 tca-163 t
C 31	15	71.4	432	BU095678 tca-163 t
C 32	15	71.4	432	BU095678 tca-163 t
C 33	15	71.4	432	BU095678 tca-163 t
C 34	15	71.4	432	BU095678 tca-163 t
C 35	15	71.4	432	BU095678 tca-163 t
C 36	15	71.4	432	BU095678 tca-163 t
C 37	15	71.4	432	BU095678 tca-163 t
C 38	15	71.4	432	BU095678 tca-163 t
C 39	15	71.4	432	BU095678 tca-163 t
C 40	15	71.4	432	BU095678 tca-163 t
C 41	15	71.4	432	BU095678 tca-163 t
C 42	15	71.4	432	BU095678 tca-163 t
C 43	15	71.4	432	BU095678 tca-163 t
C 44	15	71.4	432	BU095678 tca-163 t
C 45	15	71.4	432	BU095678 tca-163 t

Result No.	Score	Query Length	ID	Description
C 5	15	71.4	609	BU095678 tca-163 t
C 6	15	71.4	728	BU095678 tca-163 t
C 7	15	71.4	842	BU095678 tca-163 t
C 8	15	71.4	889	BU095678 tca-163 t
C 9	15	71.4	913	BU095678 tca-163 t
C 10	15	71.4	1220	BU095678 tca-163 t
C 11	15	71.4	1220	BU095678 tca-163 t
C 12	15	71.4	1220	BU095678 tca-163 t
C 13	15	71.4	1220	BU095678 tca-163 t
C 14	15	71.4	1220	BU095678 tca-163 t
C 15	15	71.4	1220	BU095678 tca-163 t
C 16	15	71.4	1220	BU095678 tca-163 t
C 17	15	71.4	1220	BU095678 tca-163 t
C 18	15	71.4	1220	BU095678 tca-163 t
C 19	15	71.4	1220	BU095678 tca-163 t
C 20	15	71.4	1220	BU095678 tca-163 t
C 21	15	71.4	1220	BU095678 tca-163 t
C 22	15	71.4	1220	BU095678 tca-163 t
C 23	15	71.4	1220	BU095678 tca-163 t
C 24	15	71.4	1220	BU095678 tca-163 t
C 25	15	71.4	1220	BU095678 tca-163 t
C 26	15	71.4	1220	BU095678 tca-163 t
C 27	15	71.4	1220	BU095678 tca-163 t
C 28	15	71.4	1220	BU095678 tca-163 t
C 29	15	71.4	1220	BU095678 tca-163 t
C 30	15	71.4	1220	BU095678 tca-163 t
C 31	15	71.4	1220	BU095678 tca-163 t
C 32	15	71.4	1220	BU095678 tca-163 t
C 33	15	71.4	1220	BU095678 tca-163 t
C 34	15	71.4	1220	BU095678 tca-163 t
C 35	15	71.4	1220	BU095678 tca-163 t
C 36	15	71.4	1220	BU095678 tca-163 t
C 37	15	71.4	1220	BU095678 tca-163 t
C 38	15	71.4	1220	BU095678 tca-163 t
C 39	15	71.4	1220	BU095678 tca-163 t
C 40	15	71.4	1220	BU095678 tca-163 t
C 41	15	71.4	1220	BU095678 tca-163 t
C 42	15	71.4	1220	BU095678 tca-163 t
C 43	15	71.4	1220	BU095678 tca-163 t
C 44	15	71.4	1220	BU095678 tca-163 t
C 45	15	71.4	1220	BU095678 tca-163 t

ALIGNMENTS

RESULT 1
BU095678/c
LOCUS
DEFINITION
tca-163 tca Trypanosoma carassii CDNA clone 01n14 5', mRNA
ACCESSION
BU095678
VERSION
BU095678.1 GI:25123402
KEYWORDS
SOURCE
ORGANISM
Trypanosoma carassii
Trypanosoma carassii
Eukaryota; Euklenozoa; Kinetoplastida; Trypanosomatidae;
Trypanosoma
1 (bases 1 to 194)
Agueiro, F., Campo, V., Cremona, L., Jager, A., Di Noia, J.M., Overath, P., Sanchez, D.O. and Frasch, A.C.
Gene discovery in the freshwater fish parasite Trypanosoma carassii: identification of trans-sialidase-like and mucin-like genes
Infect. Immun. 70 (12), 7140-7144 (2002)
CONTACT
Contact: Sanchez DO
Genomics and Bioinformatics
Instituto de Investigaciones Biologicas
Av. Gral Paz S/N, INTI, Edificio 24, B 1650 KNA, San Martin, Buenos Aires, Argentina
Tel: (54-11) 4580/7255/7
Fax: (54-11) 4752-9639
Email: dsanchez@itb.unsam.edu.ar

Sequences were basecalled with phred and vector was masked with crossmatch (see <http://www.phrap.org>). Sequences were then trimmed from both ends to remove low quality bases and masked vector.

Plate: 01 row: n column: 14
Seq primer: T7.

FEATURES
source
Location/Qualifiers
1..194

/organism="Trypanosoma carassii"
/mol_type="mRNA"
/db_xref="taxon:38249"
/clone="01n14"
/dev_stage="blood trypanostigote"
/lab_host="Goldfish (Carassius auratus)"
/clone_lib="cca"
/note="Vector: pSport1; Blood trypanostigotes were obtained from goldfish and cultured as described (Overath et al. Parasitol Res (1998) 84:343) before obtaining total RNA using TRIzol. cDNA library construction was made from polyA+ mRNA using a poly-dT oligonucleotide as primer. The cDNAs were cloned in a oriented manner using a commercial kit (SuperScript Plasmid System for cDNA Synthesis and Plasmid Cloning, Life Technologies)."

BASE COUNT
ORIGIN
60 a 35 c 40 g 59 t

Query Match 71.4%; Score 15; DB 13; Length 194;
Best Local Similarity 100.0%; Pred. No. 73;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY
1 TCGTCGACGCTTCCA 15
149 TCGTCGACGCTTCCA 135

RESULT 2
BI511039/c
LOCUS
DEFINITION
337 bp mRNA linear EST 08-APR-2002
B616000420G12.5 Bee Brain Normalized Library; B616 Apis mellifera
cDNA clone B616000420G12.5', mRNA sequence.

ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
B611039.1 GI:15361413
EST.
Apis mellifera (honeybee)
Apis mellifera

REFERENCE
AUTHORS
TITLE
1 (bases 1 to 337)
Wittfield,C.W., Band,M.R., Bonaldo,M.F., Kumar,C.G., Liu,L.,
Pardinas,J., Robertson,H.M., Soares,B. and Robinson,G.E.,
Annotated expressed sequence tags and cDNA microarrays for studies
of brain and behavior in the honey bee

JOURNAL
MEDLINE
PUBMED
21929762
11932240
Contact: Gene E. Robinson
Department of Entomology
University of Illinois
505 S. Goodwin Ave., Urbana, IL 61801, USA
Tel.: 217 265 0309
Fax: 217 244 3499
Email: genrob@life.uiuc.edu

This research was funded by the University of Illinois Critical
Research Initiatives Fund and a Burroughs-Wellcome Trust Innovation
Award in Functional Genomics to G.E. Robinson and an NSF
Postdoctoral Fellowship in Bioinformatics to C.W. Wittfield.
PCR Primers:
FORWARD: TAATACGACTCACTATAGG
BACKWARD: ATTACCTCCTAAAG

Seq primer: AGCGATACATTTTCACACGGA
High quality sequence stop: 337.
Location/Qualifiers

FEATURES

source

1..337
/organism="Apis mellifera"
/mol_type="mRNA"
/strain="mixed strains of European bees,"predominantly
A.m. ligustica"
/db_xref="taxon:7460"
/clone="B616000420G12"
/sex="Female"
/tissue_type="brain"
/dev_stage="adult worker honey bee"
/lab_host="DH10B"
/clone_lib="Bee Brain Normalized Library; B616"
/notes="Organ: brain; Vector: pT73-Pac, Site1: EcoRI;
Site2: NotI. The B616 library was contributed by the
Soares laboratory and it was constructed and normalized
as described by Bonaldo, M.F., Lennon, G. and Soares,
M.B. (1996), Genome Research 6(9): 791-806. RNA was
prepared from dissected brains of adult worker bees of
various ages and various behavioral groups."

BASE COUNT
ORIGIN
123 a 59 c 64 g 91 t

Query Match 71.4%; Score 15; DB 12; Length 337;
Best Local Similarity 100.0%; Pred. No. 78;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY
1 TCGTCGACGCTTCCA 15
264 TCGTCGACGCTTCCA 250

RESULT 3
A1945022/c
LOCUS
DEFINITION
390 bp mRNA linear EST 08-JAN-2001
bs08b02.v1 Drosophila melanogaster adult testis library Drosophila
melanogaster cDNA clone bs08b02.5', mRNA sequence.

ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
A1945022.2 GI:9990370
EST.
Drosophila melanogaster (fruit fly)
Drosophila melanogaster

REFERENCE
AUTHORS
TITLE
1 (bases 1 to 390)
Andrews,J., Bouffard,G.G., Cheadle,C., Lu,J., Becker,K.G. and
Oliver,B.

Gene discovery using computational and microarray analysis of
transcription in the drosophila melanogaster testis
Genome Res. 10 (12), 2030-2043 (2000).
1116097
On Aug 17, 1999 this sequence version replaced gi:5735420.
Contact: Brian Oliver
Laboratory of Cellular and Developmental Biology
NIDDK, National Institutes of Health
6 Center Drive MSC 2715, Bldg 6, Rm B1-13, Bethesda, MD 20892 USA
Fax: (301) 496 5239
Email: oliver@helix.nih.gov,
<http://www.niddk.nih.gov/intram/people/boliver.htm>

Tissue isolation and library construction performed at the National
Institute of Diabetes and Digestive and Kidney Diseases, NIH (see
<http://www.niddk.nih.gov/intram/people/boliver.htm>). DNA sequencing
and analyses performed by National Institutes of Health Intramural
Sequencing Center (NSC; see <http://www.nisc.nih.gov>).
plate: 08 row: b column: 02
Seq primer: M13RP1 reverse primer (ABI).

FEATURES
source

Location/Qualifiers
1..390
/organism="Drosophila melanogaster"
/mol_type="mRNA"
/strain="y[*]w[67c1]/Y"
/db_xref="taxon:7227"

```

/clone="B508b02"
/sex="male"
/dev stage="1-5 day adult"
/lab host="SOLR (Stratagene)"
/clone lib="Drosophila melanogaster adult testis library"
/notes="Organ: testis; Vector: pBluescript SK (Stratagene);
Site 1: EcoR I; Site 2: Xho I; Testes dissected from 1-5
day adult y(+) w[67c1]/Y males raised at 25°C. RNA
isolated using Trizol (Life Technologies) and a single
round of Poly(A)+ selection using Oligotex (Qiagen). cDNA
library constructed using Stratagene ZAP-cDNA synthesis
kit. Oligo dt-primed, size fractionated -1-6 kb, and
directionally cloned at EcoRI and XhoI in Uni-ZAP XR.
Following a single round of amplification pBluescript SK
plasmids were mass excised. A distribution channel for
clones is being sought, but not currently available.
Requests for clones cannot be honored."

```

BASE COUNT

```

121 a 77 c 109 g 83 t

```

ORIGIN

```

Query Match      71.4%; Score 15; DB 9; Length 390;
Best Local Similarity 100.0%; Pred. No. 79;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Oy 1 TCGTCGACGCTCGA 15
    |||||
    TCGTCGACGCTCGA 80

```

Db

```

RESULT 4
B1510669 432 bp mRNA linear EST 08-APR-2002
LOCUS B160003A20G01.5 Bee Brain Normalized Library, B16 Apis mellifera
DEFINITION cDNA clone B160003A20G01.5', mRNA sequence.
ACCESSION B1510669
VERSION B1510669.1 GI:15361043
KEYWORDS EST.
SOURCE Apis mellifera (honeybee)
ORGANISM Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
Neoptera; Endopterygota; Hymenoptera; Apoecrita; Aculeata; Apoidea;
Apidae; Apis.
1 (bases 1 to 432)
Whitfield,C.W., Band,M.R., Bonaldo,M.F., Kumar,C.G., Liu,L.,
Pardinas,J., Robertson,H.M., Soares,B. and Robinson,G.E.,
Annotated expressed sequence tags and cDNA microarrays for studies
of brain and behavior in the honey bee
Genome Res. 12 (4), 555-566 (2002)

```

```

REFERENCE
AUTHORS
TITLE
JOURNAL
MEDLINE
PUBMED
COMMENT
Contact: Gene E. Robinson
Department of Entomology
University of Illinois
505 S. Goodwin Ave., Urbana, IL 61801, USA
Tel: 217 265 0309
Fax: 217 244 3499
Email: genrobi@life.uiuc.edu
This research was funded by the University of Illinois Critical
Research Initiatives Fund and a Burroughs-Wellcome Trust Innovation
Award in Functional Genomics to G.E. Robinson and an NSF
Postdoctoral Fellowship in Bioinformatics to C.W. Whitfield.
PCR Primers
FORWARD: TAAATGACTCACTATAGG
BACKWARD: ATTACCTCTACTAAG
Plate: B160003A20 row: G column: 01
Seq primer: AGCGATACAAATTTCACACAGA
High quality sequence stop: 432.
Location/Qualifiers
1..432
/organism="Apis mellifera"
/mol_type="mRNA"
/strain="mixed strains of European bees, predominantly
A.m. ligustica"

```

FEATURES

```

source

```

```

/db xref="taxon:7460"
/clone="B160003A20G01"
/sex="female"
/tissue type="brain"
/dev stage="adult worker honey bee"
/lab host="DH10B"
/clone lib="Bee Brain Normalized Library, B16"
/notes="Organ: brain; Vector: pRTT3-Pac; Site 1: EcoRI;
Site 2: NotI; The B16 library was constructed by the
Soares laboratory and it was constructed and normalized
as described by Bonaldo, M.F., Lennon, G. and Soares,
M.B. (1996), Genome Research 6(9): 791-806. RNA was
prepared from dissected brains of adult worker bees of
various ages and various behavioral groups."

```

BASE COUNT

```

163 a 69 c 102 g 98 t

```

ORIGIN

```

Query Match      71.4%; Score 15; DB 12; Length 432;
Best Local Similarity 100.0%; Pred. No. 80;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Oy 1 TCGTCGACGCTCGA 15
    |||||
    TCGTCGACGCTCGA 44

```

Db

```

RESULT 5
A0623639 609 bp DNA linear GSS 16-JUN-1999
LOCUS HS_5377_A2_F05 SPEE RPCI-11 Human Male BAC Library Homo sapiens
DEFINITION genomic clone Plate=953 Col=10 Row=K, genomic survey sequence.
ACCESSION A0623639
VERSION A0623639.1 GI:5086119
KEYWORDS GSS.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 609)
Mahairas,G.G., Wallace,J.C., Smith,K., Swartzell,S., Holzman,T.,
Keller,A., Shaker,R., Furlong,J., Young,J., Zhao,S., Adams,M.D. and
Hood,L.
Sequence-tagged connectors: A sequence approach to mapping and
scanning the human genome
Proc. Natl. Acad. Sci. U.S.A. 96 (17), 9739-9744 (1999)
99380589
MEDLINE
PUBMED
COMMENT
Contact: Mahairas GG, Wallace JC, Hood L
High Throughput Sequencing Center
University of Washington
401 Queen Anne Avenue North, Seattle, WA 98109, USA
Tel: (206) 616-3618
Fax: (206) 616-3887
Email: jwallace@u.washington.edu
Clones are derived from the human BAC library RPCI-11. For BAC
library availability, please contact Pieter de Jong
(pjeter@dejong.med.buffalo.edu). Clones may be purchased from
BACPAC Resources (http://bacpac.med.buffalo.edu/ordering/bac.htm)
or from Research Genetics (info@resgen.com). BAC end web Server:
http://www.htsc.washington.edu
Plate: 953 row: K column: 10
Seq primer: SP6
Class: BAC ends
High quality sequence stop: 609.
Location/Qualifiers
1..609
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
/clone="Plate=953 Col=10 Row=K"
/sex="male"
/clone lib="RPCI-11 Human Male BAC Library"
/notes="Vector: pBACe3.6; Site 1: EcoRI; Site 2: EcoRI;

```

FEATURES

```

source

```

```

/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
/clone="Plate=953 Col=10 Row=K"
/sex="male"
/clone lib="RPCI-11 Human Male BAC Library"
/notes="Vector: pBACe3.6; Site 1: EcoRI; Site 2: EcoRI;

```

Male blood DNA was isolated from one randomly chosen donor and partially digested with a combination of EcoRI and EcoRII Methylase. Size selected DNA was cloned into the pBACE3.6 vector at EcoRI sites"

BASE COUNT 185 a 124 c 162 g 125 t 13 others

Query Match 71.4%; Score 15; DB 28; Length 609;
Best Local Similarity 100.0%; Pred. No. 84;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TCGTCGACGTCGA 15
|||||
Db 335 TCGTCGACGTCGA 349

RESULT 6 728 bp DNA linear GSS 08-MAY-2002
BH816458
LOCUS BH816458
DEFINITION AM_Ba0021J24f Apis mellifera Apis mellifera genomic clone
ACCESSION AM_Ba0021J24f, genomic survey sequence.
VERSION BH816458
KEYWORDS GSS.
SOURCE Apis mellifera (honeybee)
ORGANISM Apis mellifera
Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
Neoptera; Endopterygota; Hymenoptera; Apocrita; Aculeata; Apoidea;
Apoidea; Apis.
1 (bases 1 to 728)
Tomkins,J.P., Luo,M., Hunt,G., Main,D., Frisch,D., Page,P.E.,
Guzman-Nova,E. and Wing,R.A.
Development of Genomic Resources for honey bee (Apis mellifera L.):
BAC Library Construction, Preliminary STC Analysis, and
Identification of Clones Associated With Behavioral Traits
Unpublished
Contact: Tomkins JP
Clemson University Genomics Institute
Clemson University
100 Jordan Hall, Clemson University, Clemson, SC 29634, USA
Tel: 864 656 7288
Fax: 864 656 4293
Email: jtmkns@clemson.edu
Total hg bases = 231
Seq primer: TAATACGACTCACTATAGG
Class: BAC ends
High quality sequence start: 52
High quality sequence stop: 502.
Location/Qualifiers

FEATURES

source

1. 728
/organism="Apis mellifera"
/mol_type="genomic DNA"
/strain="Africanized honey bee"
/db_xref="taxon:7460"
/clone="AM_Ba0021J24f"
/tissue_type="larva"
/lab_host="E. coli"
/clone_1lb="Apis mellifera"
/note="Vector: pCUGIBAC-1; Site 1: HindIII; Site 2: NotI;
For more details on library preparation and sequence
analysis see
http://www.genome.clemson.edu/projects/stc/bee/AM_Ba/ To
order clones from this library see
http://www.genome.clemson.edu/orders "
BASE COUNT 227 a 134 c 156 g 207 t 4 others

Query Match 71.4%; Score 15; DB 28; Length 728;
Best Local Similarity 100.0%; Pred. No. 86;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 GAACGTCGAGATCA 20
|||||

Db 118 GAACGTCGAGATCA 132

RESULT 7 842 bp DNA linear GSS 30-APR-2003
BZ391656/c
LOCUS BZ391656
DEFINITION EINC064TR_EI_10_12_KB Entamoeba invadens genomic clone EINC064,
genomic survey sequence.
ACCESSION BZ391656
VERSION BZ391656.1 GI:30238193
KEYWORDS GSS.
SOURCE Entamoeba invadens
ORGANISM Entamoeba invadens
Eukaryota; Entamoebidae; Entamoeba.
1 (bases 1 to 842)
Loftus,B., Wang,Z., Roncaglia,P., Van Aken,S. and Fraser,C.
Gene discovery in the Entamoeba invadens genome
Unpublished
Other_GSSes: EINC064TR
Contact: Brendan Loftus
Department of Eukaryotic Genomics
TIGR
9712 Medical Center Drive, Rockville, MD 20850, USA
Tel: 301-838-3543
Fax: 301-838-0208
Email: ent@tigr.org
DNA was provided by Daniel Eichinger
Seq primer: TR
Class: sheared ends.
Location/Qualifiers

FEATURES
source

1. 842
/organism="Entamoeba invadens"
/mol_type="genomic DNA"
/strain="IP-1"
/db_xref="taxon:33085"
/clone="EINC064"
/clone_1lb="EI_10_12_KB"
/note="Vector: pHS2; Site 1: BstXI; Total genomic DNA was
isolated from early log phase trophozoites of E. invadens
IP-1 using a Qiagen plant DNA extraction kit. A shotgun
medium-size plasmid library (average insert size of 10 -
12 kb) was generated by random mechanical shearing of E.
invadens genomic DNA, repairing the ends of DNA fragments
with T4 Polymerase, adding BstXI adaptors and ligating
into the BstXI site of a pUC-derived vector pHS2."
281 a 152 c 140 g 269 t

BASE COUNT

ORIGIN

Query Match 71.4%; Score 15; DB 29; Length 842;
Best Local Similarity 100.0%; Pred. No. 87;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 AACGTCGAGATGAT 21
|||||
Db 796 AACGTCGAGATGAT 782

RESULT 8 889 bp mRNA linear EST 31-MAY-2003
CD375545
LOCUS CD375545
DEFINITION Phaeodactylum tricornutum Uni-Zap XR Phaeodactylum
tricornutum cDNA 5', mRNA sequence.
ACCESSION CD375545
VERSION CD375545.1 GI:31251159
KEYWORDS EST.
SOURCE Phaeodactylum tricornutum
ORGANISM Phaeodactylum tricornutum
Eukaryota; stramenopiles; Bacillariophyta; Bacillariophyceae;
Bacillariophycidae; Naviculales; Phaeodactylaceae; Phaeodactylum.
1 (bases 1 to 889)
Scala,S., Carels,N., Falciatore,A., Chiusano,M.L. and Bowler,C.
Genome properties of the diatom Phaeodactylum tricornutum
Plant Physiol. 129 (3), 993-1002 (2002)

MEDLINE 2211123
PUBMED 1211455
COMMENT Contact: Bowler C
Laboratory of Molecular Plant Biology
Stazione Zoologica 'Anton Dohrn'
Villa Comunale, I-80121, Napoli, Italy
Tel: 39 081 583 3268/3211
Fax: 39 081 764 1355
Email: chris@alpha.szn.it
Diatom EST Database (<http://aves.hshgen.szb.wiener.ac.at>)
Seq primer: T3 backward
POLYAs: 5'

FEATURES
source
1. 889
/organism="Phaeodactylum tricornutum"
/mol_type="rRNA"
/db_xref="taxon:2850"
/cell_line="CCMP632"
/clone_lib="Phaeodactylum tricornutum Uni-Zap XR"
/note="Vector: Uni-Zap XR vector; Site_1: Eco RI; Site_2: Xho I"

BASE COUNT 216 a 247 c 181 g 214 t 31 others

ORIGIN

Query Match 71.4%; Score 15; DB 14; Length 889;
Best Local Similarity 100.0%; Pred. No. 88;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 7 AACGTTGAGATGAT 21
|||||
197 AACGTTGAGATGAT 183

Db 197 AACGTTGAGATGAT 183

RESULT 9
LOCUS BX455352 913 bp mRNA linear EST 22-MAY-2003
DEFINITION BX455352 Homo sapiens FETAL BRAIN Homo sapiens cDNA clone
CS0DF022YA13 3-PRIME, mRNA sequence.
ACCESSION BX455352
VERSION BX455352.1 GI:31019187
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 913)
Li, W.B., Gruber, C., Jessee, J., and Polyes, D.
Full-length cDNA libraries and normalization
Unpublished
Contact: Genoscope - Centre National de Sequencage
BP 191 91006 Evry cedex - France
Email: seqref@genoscope.cns.fr, Web: www.genoscope.cns.fr
Library was constructed by Life Technologies, a division of
Invitrogen. This sequence belongs to sequence cluster 10667.f. For
more information about this cluster, see
<http://www.genoscope.cns.fr/cgi-bin/cluster.cgi?seq=CS0BAK038CA04NM2&cluster=10667.f>. Contact :
Feng Liang, Email: liang@lifetech.com URL :
http://fulllength.invitrogen.com/Invitrogen/Corporation_1600_Faraday_Avenue_Genoscope_sequence_ID:_CS0BAK038CA04NM2.
Location/Qualifiers
1. 913
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="CS0DF022YA13"
/issue_type="FETAL BRAIN"
/dev_stage="fetal"
/clone_lib="Homo sapiens FETAL BRAIN"
/note="Organ: Brain; Vector: PCWSPORT_6; 1st strand cDNA
was primed with a NotI-oligo(dT) primer. Five prime end
enriched, double-strand cDNA was digested with Not I and

BASE COUNT 304 a 199 c 163 g 246 t 1 others

ORIGIN

Query Match 71.4%; Score 15; DB 13; Length 913;
Best Local Similarity 100.0%; Pred. No. 88;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 6 GAACGTTGAGATGA 20
|||||
900 GAACGTTGAGATGA 886

Db 900 GAACGTTGAGATGA 886

RESULT 10
LOCUS CC235774 1220 bp DNA linear GSS 12-MAY-2003
DEFINITION CH261-139L19_RML.2 CH261 Gallus gallus genomic clone CH261-139L19,
genomic survey sequence.
ACCESSION CC235774
VERSION CC235774.1 GI:30562437
KEYWORDS GSS.
SOURCE Gallus gallus (chicken)
ORGANISM Gallus gallus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Archosauria; Aves; Neognathae; Galliformes; Phasianidae;
Phasianinae; Gallus.
1 (bases 1 to 1220)
Kremetzki, C., Higginbotham, J., Wylie, K., Carter, J., McPherson, J.,
Warren, W., Graves, T., Mardis, E., and Wilson, R.
Gallus gallus BAC End Reads
Unpublished
Contact: Richard K. Wilson
Genome Sequencing Center
Washington University School of Medicine
Email: submissions@watson.wustl.edu
Insert Length: 182000 Std Error: 0.00
Seq primer: RML TACGACTCCTATAGGAGA
Class: BAC ends
High quality sequence start: 473
High quality sequence stop: 541.
Location/Qualifiers
1. 1220
/organism="Gallus gallus"
/mol_type="genomic DNA"
/strain="Red Jungle Fowl"
/db_xref="taxon:9031"
/clone="CH261-139L19"
/sex="female"
/cell_line="UCD001, inbred 256"
/clone_lib="CH261"
/note="Vector: pTARBAC2.1; Site_1: EcoRI; Site_2: EcoRI;
CH261 Female Chicken library - for library and clone
ordering information: <http://www.chori.org/bacpac>"

BASE COUNT 320 a 330 c 171 g 399 t

ORIGIN

Query Match 71.4%; Score 15; DB 29; Length 1220;
Best Local Similarity 100.0%; Pred. No. 91;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 7 AACGTTGAGATGAT 21
|||||
461 AACGTTGAGATGAT 447

Db 461 AACGTTGAGATGAT 447

RESULT 11
LOCUS CNS09N54 108 bp mRNA linear HTC 08-JAN-2003
DEFINITION CNS09N54
Single read from an extremity of a full-length cDNA clone made from
Anopheles gambiae total adult females. 5-PRIME end of clone
FK0AC5AH09 of strain 6-9 of Anopheles gambiae (African malaria
mosquito).

ACCESSION BX066068
 VERSION BX066068.1 GI:27639349
 KEYWORDS HTC.
 SOURCE Anopheles gambiae (African malaria mosquito)
 ORGANISM Anopheles gambiae
 Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
 Neoptera; Endopterygota; Diptera; Nematocera; Culicoidae;
 Anopheles.
 REFERENCE 1 (bases 1 to 108)
 AUTHORS Genoscope.
 TITLE Direct Submission
 JOURNAL Submitted (06-JAN-2003) Genoscope - Centre National de Sequencage :
 BP 101 91006 Evry cedex - FRANCE (E-mail : seqref@genoscope.cns.fr
 - Web : www.genoscope.cns.fr)
 FEATURES
 source Location/Qualifiers
 1..108
 /organism="Anopheles gambiae"
 /mol_type="mRNA"
 /db_xref="taxon:7165"
 /clone="FR0AAC5AH09"
 /plasmid="PME18S-FL"
 /note="end : 5-PRIME"
 BASE COUNT 21 a 31 c 34 g 22 t
 ORIGIN
 Query Match 66.7%; Score 14; DB 11; Length 108;
 Best Local Similarity 100.0%; Pred. No. 2.6e+02;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 5 CGAACGTTGAGAT 18
 |||||
 |||||
 Db 61 CGAACGTTGAGAT 48
 |||||
 |||||
 |||||
 RESULT 12
 LOCUS R04873 168 bp mRNA linear EST 31-MAR-1995
 DEFINITION p33h10.r1 Kuwabara Mixed stage C. briggsae Caenorhabditis briggsae
 cDNA, mRNA sequence.
 ACCESSION R04873
 VERSION R04873.1 GI:754609
 KEYWORDS EST.
 SOURCE Caenorhabditis briggsae
 ORGANISM Caenorhabditis briggsae
 Eukaryota; Metazoa; Nematoda; Chromadorea; Rhabditida; Rhabditoidea
 ; Rhabditidae; Pelodidae; Caenorhabditis.
 1 (bases 1 to 168)
 REFERENCE 1
 AUTHORS Hillier,L., Chiapelli,B., Chissee,S., Clark,N., Couch,J., Dubuque
 ,T., Hawkins,M., Holman,M., Hultman,M., Kucaba,T., Kuwabara,P., Le
 ,M., Marais,E., Marra,M., Parsons,J., Rifkin,L., Rohlfing,T., Tan
 ,F., Trevasik,E., Waterston,R., Wohlmann,P. and Wilson,R.
 TITLE Washington University Caenorhabditis briggsae EST project
 JOURNAL Unpublished
 COMMENT Contact: Marra MA
 Washington University Genome Sequencing Center
 Washington University School of Medicine
 4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
 Tel: 314 286 1455
 Fax: 314 286 1810
 Email: mmarr@wustl.edu
 PCR_F: TGTAAACGACGCGCAGTACAGTTCAGCTTCG
 PCR_R: CAGGAACAGCTATGACCTTATGATTTCTTCAGAGTA
 Source: Washington University Genome Sequencing Center
 PCR amplified DNA is available from Washington University Genome
 Sequencing Center. Aliquots of the library may be requested from P.
 Kuwabara (pek@mc-lmb.cam.ac.uk).
 Seq primer: Commercially available M13 reverse dye primer.
 Location/Qualifiers
 1..168
 /organism="Caenorhabditis briggsae"
 /mol_type="mRNA"
 /strain="G16 Gujarat"

/db_xref="taxon:6238"
 /clone_lib="Kuwabara Mixed stage C. briggsae"
 /note="Vector: Lambda gt10; Site_1: EcoRI; Site_2: EcoRI;
 Stage:mixed, Sex:hermaphrodite. Library construction:
 First strand oligo(dT) primed. Second strand was as per
 Gubler/Hoffman. Ligated to EcoRI adaptors. Library is
 non-directional. Library is non-normalized. Library
 constructed by P.E. Kuwabara. Additional details on
 construction of the library are described in P.E.
 Kuwabara and S. Shah, NAR 22: 4414 - 4418 (1994). Adaptor
 sequence: GAATTC CGTTCGTCGCG"
 BASE COUNT 46 a 42 c 42 g 38 t
 ORIGIN
 Query Match 66.7%; Score 14; DB 14; Length 168;
 Best Local Similarity 100.0%; Pred. No. 2.8e+02;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 TCCTCGAACGTTG 14
 |||||
 |||||
 Db 148 TCCTCGAACGTTG 161
RESULT 13			
LOCUS A1186214/c 298 bp mRNA linear EST 10-JAN-1997			
DEFINITION T3860 MWAT4 bloodstream form of serodeme WRATat1.1 Trypanosoma			
brucei rhodesiense cDNA 5', mRNA sequence.			
ACCESSION A1186214			
VERSION A1186214.1 GI:1172670			
KEYWORDS EST.			
SOURCE Trypanosoma brucei rhodesiense			
ORGANISM Trypanosoma brucei rhodesiense			
Eukaryota; Euzlenozoa; Kinetoplastida; Trypanosomatidae;			
Trypanosoma.			
1 (bases 1 to 298)			
REFERENCE 1			
AUTHORS Dikeng,A., Donelson,J.E. and Majiwa,P.A.O.			
TITLE Generation of expressed sequence tags as physical landmarks in the			
genome of Trypanosoma brucei			
JOURNAL Unpublished			
COMMENT Contact: Majiwa PAO			
Molecular Biology Unit			
International Livestock Research Institute			
P.O. Box 30709, Nairobi, Kenya			
Tel: 254-2 630743			
Fax: 254-2 631499			
Email: p.majiwa@cgiar.com			
Seq primer: T3 primer			
Location/Qualifiers			
1..298			
/organism="Trypanosoma brucei rhodesiense"			
/mol_type="mRNA"			
/sub_species="rhodesiense"			
/db_xref="taxon:31286"			
/clone_lib="MWAT4 bloodstream form of serodeme WRATat1.1"			
/note="Vector: Lambda ZAP II (Stratagene) ; Site_1: EcoRI;			
Site_2: XhoI; The mRNA was purified from a cloned			
population of bloodstream trypanosomes reexpressing the			
MWAT4 metacyclic variant surface glycoprotein (VSG). A			
unidirectional oligo dt-primed EcoRI/XhoI cDNA library was			
constructed in lambda ZAP II (Stratagene)."			
BASE COUNT 93 a 63 c 86 g 56 t			
ORIGIN			
Query Match 66.7%; Score 14; DB 9; Length 298;			
Best Local Similarity 100.0%; Pred. No. 3e+02;			
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;			
QY 8 ACCTTCGAGATGAT 21			
Db 263 ACCTTCGAGATGAT 250			

RESULT 14
CNS09090 348 bp mRNA linear HTC 08-JAN-2003
LOCUS Single read from an extremity of a full-length cDNA clone made from
DEFINITION Anopheles gambiae total adult females. 5-PRIME end of clone
FK0AC7AB01 of strain 6-9 of Anopheles gambiae (African malaria
mosquito).
VERSION BX070096
KEYWORDS GI:27643377
SOURCE HTc.
ORGANISM Anopheles gambiae (African malaria mosquito)
Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
Neoptera; Endopterygota; Diptera; Nematocera; Culicoidae;
Anopheles.
REFERENCE 1 (bases 1 to 348)
AUTHORS Genoscope.
TITLE Direct Submission
JOURNAL Submitted (06-JAN-2003) Genoscope - Centre National de Sequencage :
BP 191 91006 EVRY cedex - FRANCE (E-mail : seqref@genoscope.cns.fr
- Web : www.genoscope.cns.fr)
FEATURES
source Location/Qualifiers
1..348
/organism="Anopheles gambiae"
/mol_type="mRNA"
/strain="6-9"
/db_xref="taxon:7165"
/clone="FK0AC7AB01"
/plasmid="pME18S-FL"
/note="end : 5-PRIME"
BASE COUNT 81 a 101 c 114 g 52 t
ORIGIN
Query Match 66.7%: Score 14; DB 11; Length 348;
Best Local Similarity 100.0%; Pred. No. 3e+02; 0; Indels 0; Gaps 0;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 5 CGACGCTCGAGAT 18
DB 263 CGACGCTCGAGAT 250
RESULT 15
BIS07844 387 bp mRNA linear EST 08-APR-2002
LOCUS BB170008B10E04.5 Bee Brain Normalized/Subtracted Library, BB17 Apis
DEFINITION mellifera cDNA clone BB170008B10E04.5, mRNA sequence.
ACCESSION BIS07844
VERSION BIS07844.1 GI:15358218
KEYWORDS EST.
SOURCE Apis mellifera (honeybee)
ORGANISM Apis mellifera
Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
Neoptera; Endopterygota; Hymenoptera; Apocrita; Aculeata; Apoidea;
Apidae; Apis.
REFERENCE 1 (bases 1 to 387)
AUTHORS Whitfield,C.W., Band,M.R., Bonaldo,M.F., Kumar,C.G., Liu,L.,
Pardine,J., Robertson,H.M., Soares,B. and Robinson,G.B.,
Annotated expressed sequence tags and cDNA microarrays for studies
of brain and behavior in the honey bee
JOURNAL Genome Res. 12 (4), 555-566 (2002)
MEDLINE 21929762
PUBMED 11932240
COMMENT Contact: Gene E. Robinson
Department of Entomology
University of Illinois
505 S. Goodwin Ave., Urbana, IL 61801, USA
Tel: 217 265 0309
Fax: 217 244 3499
Email: generobi@life.uiuc.edu
This research was funded by the University of Illinois Critical
Research Initiatives Fund and a Burroughs-Wellcome Trust Innovation
Award in Functional Genomics to G.E. Robinson and an NSF

Postdoctoral Fellowship in Bioinformatics to C.W. Whitfield.
PCR Primers
FORWARD: TATACGACTCAGTATAGG
BACKWARD: ATTACCTCTACTAAG
Plate: BB170008B10 row: E column: 04
Seq primer: ACCGATACAAATTCACACAGA
High quality sequence stop: 387.
FEATURES
source Location/Qualifiers
1..387
/organism="Apis mellifera"
/mol_type="mRNA"
/strain="mixed strains of European bees, predominantly
A.m. ligustica"
/db_xref="taxon:7460"
/clone="BB170008B10E04"
/sex="female"
/tissue_type="brain"
/dev_stage="adult worker honey bee"
/lab_host="DH10B"
/clone_lib="Bee Brain Normalized/Subtracted Library, BB17"
/note="Organ: brain; Vector: pRT3-Pac; Site 1: Ecot1;
Site 2: Not1; This BB17 cDNA library was generated by
subtraction of the BB16 library with 4000 previously
sequenced clones. The BB16 library was contributed by the
Soares laboratory and it was constructed and normalized
as described by Bonaldo, M.F., Lennon, G. and Soares,
M.B. (1996). Genome Research 6(9): 791-806. RNA was
prepared from dissected brains of adult worker bees of
various ages and various behavioral groups."
BASE COUNT 125 a 71 c 95 g 96 t
ORIGIN
Query Match 66.7%: Score 14; DB 12; Length 387;
Best Local Similarity 100.0%; Pred. No. 3e+02; 0; Indels 0; Gaps 0;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 8 ACGTTCGAGATGAT 21
DB 228 ACGTTCGAGATGAT 241

Search completed: December 19, 2003, 13:40:52
Job time : 1316 secs

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: December 19, 2003, 12:58:44 ; Search time 1195 Seconds

(without alignments)
718.914 Million cell updates/sec

Title: US-10-033-243-132

Perfect score: 21

Sequence: 1 tcgtcgaacgttcgaatgatc 21

Scoring table: OLIGO_NUC
Gapop 60.0 , Gapext 60.0

Searched: 2888711 seqs, 2045481386 residues

Word size : 0

Total number of hits satisfying chosen parameters: 5777422

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Listing first 45 summaries

Database : GenEmbl:
1: gb_ba:*
2: gb_hcg:*
3: gb_in:*
4: gb_om:*
5: gb_ov:*
6: gb_pat:*
7: gb_ph:*
8: gb_pl:*
9: gb_pr:*
10: gb_ro:*
11: gb_sfg:*
12: gb_sy:*
13: gb_un:*
14: gb_vl:*
15: em_ba:*
16: em_fun:*
17: em_hum:*
18: em_in:*
19: em_mu:*
20: em_om:*
21: em_or:*
22: em_ov:*
23: em_pat:*
24: em_ph:*
25: em_pl:*
26: em_ro:*
27: em_sfg:*
28: em_un:*
29: em_vl:*
30: em_hcg_hum:*
31: em_hcg_inv:*
32: em_hcg_other:*
33: em_hcg_mus:*
34: em_hcg_pln:*
35: em_hcg_rtd:*
36: em_hcg_mam:*
37: em_hcg_vrt:*
38: em_sy:*
39: em_hcgo_hum:*
40: em_hcgo_mus:*
41: em_hcgo_other:*

score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	21	100.0	21	6	AX592442
2	19	90.5	19	6	AX592329
3	19	90.5	22	6	AX592340
4	16	76.2	18	6	AX592324
5	16	76.2	119972	2	AP004029
6	16	76.2	126038	8	AP000367
7	16	76.2	144952	2	AP005629
8	16	76.2	146568	2	AC141727
9	16	76.2	166304	2	AC130730
10	15	71.4	22	6	AR268334
11	15	71.4	22	6	AR287741
12	15	71.4	22	6	AR287743
13	15	71.4	22	6	AR308057
14	15	71.4	22	6	AX036945
15	15	71.4	22	6	AX046993
16	15	71.4	22	6	AX083675
17	15	71.4	22	6	AX083676
18	15	71.4	22	6	AX135650
19	15	71.4	22	6	AX148636
20	15	71.4	22	6	AX148637
21	15	71.4	22	6	AX250701
22	15	71.4	22	6	AX250702
23	15	71.4	22	6	AX252291
24	15	71.4	22	6	AX252292
25	15	71.4	22	6	AX252509
26	15	71.4	22	6	AX252510
27	15	71.4	22	6	AX252520
28	15	71.4	22	6	AX252521
29	15	71.4	22	6	AX252934
30	15	71.4	22	6	AX252935
31	15	71.4	22	6	AX253113
32	15	71.4	22	6	AX253114
33	15	71.4	22	6	AX253123
34	15	71.4	22	6	AX253124
35	15	71.4	22	6	AX468499
36	15	71.4	22	6	AX592312
37	15	71.4	22	6	AX592322
38	15	71.4	22	6	AX592332
39	15	71.4	22	6	AX592350
40	15	71.4	22	6	AX592355
41	15	71.4	22	6	AX592356
42	15	71.4	22	6	AX592369
43	15	71.4	22	6	AX720306
44	15	71.4	22	6	BD009235
45	15	71.4	22	6	BD182369

ALIGNMENTS

RESULT 1
AX592442
LOCUS AX592442 21 bp DNA linear PAT 27-JAN-2003
DEFINITION Sequence 132 from Patent WO02052002.
ACCESSION AX592442
VERSION AX592442.1 GI:27950544
KEYWORDS
SOURCE
ORGANISM
synthetic construct
synthetic construct
artificial sequences.
REFERENCE
1 Fearon, K.L. and Dina, D.
Immunomodulatory polynucleotides and methods of using the same
Patent: WO 02052002-A 132 04-JUL-2002;
Dynavax Technologies Corporation (US)

Pred. No. is the number of results predicted by chance to have a

```

FEATURES
  source
    location/Qualifiers
      1. .21
        /organism="synthetic construct"
        /mol_type="genomic DNA"
        /db_xref="taxon:32630"
        /note="Polynucleotide containing CG"
BASE COUNT
  5 a 4 c 6 g 6 t
ORIGIN

Query Match
  Best Local Similarity 100.0%; Score 21; DB 6; Length 21;
  Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY
  1 TCGTCGAACGTTCGAGATG 21
  |||||
  1 TCGTCGAACGTTCGAGATG 21

RESULT 2
  LOCUS AX592329 19 bp DNA linear PAT 27-JAN-2003
  DEFINITION Sequence 19 from Patent WO02052002.
  ACCESSION AX592329
  VERSION AX592329.1 GI:27950431
  KEYWORDS
  SOURCE
    synthetic construct
    synthetic construct
    artificial sequences.
  REFERENCE
    1 Fearon,K.L. and Dina,D.
      Immunomodulatory polynucleotides and methods of using the same
      Patent: WO 02052002-A 19 04-JUL-2002;
      Dynavax Technologies Corporation (US)
      Location/Qualifiers
        1. .19
          /organism="synthetic construct"
          /mol_type="genomic DNA"
          /db_xref="taxon:32630"
          /note="Polynucleotide containing CG"
BASE COUNT
  4 a 4 c 6 g 5 t
ORIGIN

Query Match
  Best Local Similarity 90.5%; Score 19; DB 6; Length 19;
  Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY
  1 TCGTCGAACGTTCGAGATG 19
  |||||
  1 TCGTCGAACGTTCGAGATG 19

Db
  1 TCGTCGAACGTTCGAGATG 19

RESULT 3
  LOCUS AX592340 22 bp DNA linear PAT 27-JAN-2003
  DEFINITION Sequence 30 from Patent WO02052002.
  ACCESSION AX592340
  VERSION AX592340.1 GI:27950442
  KEYWORDS
  SOURCE
    synthetic construct
    synthetic construct
    artificial sequences.
  REFERENCE
    1 Fearon,K.L. and Dina,D.
      Immunomodulatory polynucleotides and methods of using the same
      Patent: WO 02052002-A 30 04-JUL-2002;
      Dynavax Technologies Corporation (US)
      Location/Qualifiers
        1. .22
          /organism="synthetic construct"
          /mol_type="genomic DNA"
          /db_xref="taxon:32630"
          /note="Polynucleotide containing CG"
FEATURES
  source
    location/Qualifiers
      1. .22
        /organism="synthetic construct"
        /mol_type="genomic DNA"
        /db_xref="taxon:32630"
        /note="Polynucleotide containing CG"
BASE COUNT
  5 a 4 c 7 g 6 t

```

```

ORIGIN
Query Match          90.5%; Score 19; DB 6; Length 22;
Best Local Similarity 100.0%; Pred. No. 0.28;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 TCGTCGAACGTTTCGAGATG 19
    |||||
4 TCGTCGAACGTTTCGAGATG 22
    |||||

RESULT 4
AX592324 18 bp DNA linear PAT 27-JAN-2002
LOCUS
DEFINITION Sequence 14 from Patent WO02052002.
ACCESSION AX592324
VERSION AX592324.1 GI:27950426
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1 Fearon,K.L. and Dina,D.
AUTHORS Immunomodulatory polynucleotides and methods of using the same
TITLE Patent: WO 02052002-A, 14 04-JUL-2002;
JOURNAL Dynavax Technologies Corporation (US)
FEATURES
Source
1..18
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
/notes="Polynucleotide containing CG"

BASE COUNT 4 a 4 c 5 g 5 t

ORIGIN
Query Match          76.2%; Score 16; DB 6; Length 18;
Best Local Similarity 100.0%; Pred. No. 21;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 4 TCGAACGTTTCGAGATG 19
    |||||
3 TCGAACGTTTCGAGATG 18
    |||||

RESULT 5
AP004029 119972 bp DNA linear HTG 21-MAR-2002
LOCUS
DEFINITION Oryza sativa (japonica cultivar-group) chromosome 2 clone
OJ1136.D07, *** SEQUENCING IN PROGRESS ***.
ACCESSION AP004029
VERSION AP004029.1 GI:15130691
KEYWORDS HTG, HTGS, PHASE2.
SOURCE
ORGANISM
Oryza sativa (japonica cultivar-group)
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
Ehrhartoideae; Oryzaceae; Oryza.
1
Sasaki,T., Matsumoto,T. and Yamamoto,K.
Oryza sativa nipponbare(Ga3) genomic DNA, chromosome 2, BAC
clone:OJ1136.D07
Published Only in Database (2001)
2 (bases 1 to 119972)
Sasaki,T., Matsumoto,T. and Yamamoto,K.
Direct Submission
Submitted (08-AUG-2001) Takuji Sasaki, National Institute of
Agrobiological Resources, Rice Genome Research Program, Kamondai
2-1-2, Tsukuba, Ibaraki 305-8602, Japan
(E-mail:tsasakionias.affrc.go.jp, URL:http://xgp.dna.affrc.go.jp/,
Tel:81-298-38-7441, Fax:81-298-38-7468)
The nucleotide sequence of this BAC clone was generated by
combining Monsanto and RGP-Japan sequencing data.
NOTE: It currently consists of 1 contigs. Gaps between the contigs

```

are represented as runs of N. The order of the pieces is believed to be correct as given, however the sizes of the gaps between them are based on estimates that have provided by the submitter. This sequence will be replaced by the finished sequence as soon as it is available and the accession number will be preserved.

* NOTE: This is a 'working draft' sequence.
* This sequence will be replaced
* by the finished sequence as soon as it is available and
* the accession number will be preserved.

FEATURES
source
1. 119972
/organism="Oryza sativa (japonica cultivar-group)"
/mol_type="genomic DNA"
/cultivar="Nipponbare"
/db_xref="taxon:39947"
/chromosome="2"
/clone="OJ136.D07"
/accession="25414 g 34818 t"

BASE COUNT 34735 a 25005 c 25414 g 34818 t

ORIGIN
Query Match 76.2% Score 16; DB 2; Length 119972;
Best Local Similarity 100.0%; Pred No. 25;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 5 CGAAGCTTCGAGATGA 20
|||||
DB 38384 CGAAGCTTCGAGATGA 38399

RESULT 6
AP000367/c 126038 bp DNA linear PLN 21-MAR-2002
LOCUS
DEFINITION Oryza sativa (japonica cultivar-group) genomic DNA, chromosome 2,
clone:PO437H03 (contig b).
ACCESSION AP000367
VERSION AP000367.1 GI:5441876
KEYWORDS
SOURCE Oryza sativa (japonica cultivar-group)
ORGANISM Oryza sativa (japonica cultivar-group); Embryophyta; Tracheophyta;
Eukaryota; Viridiplantae; Streptophyta; Liliopsida; Poales; Poaceae;
Eriocaridaceae; Oryzaceae; Oryza.

REFERENCE
1 Sasaki, T., Matsumoto, T. and Yamamoto, K.
Oryza sativa Nipponbare(GA3) genomic DNA, chromosome 2, PAC
clone:PO437H03 (contig b)
Published Only in Database (1999)
2 (bases 1 to 126038)
Sasaki, T., Matsumoto, T. and Yamamoto, K.
Direct Submission
Submitted (06-JUL-1999) Takuji Sasaki, National Institute of
Agrobiological Resources, Rice Genome Research Program, Kannondai
2-1-2, Tsukuba, Ibaraki 305-8602, Japan
E-mail:tsasaki@abrr.affrc.go.jp, URL:ftp://rgp.dna.affrc.go.jp/,
Tel:81-298-38-7441, Fax:81-298-38-7468

COMMENT
This PAC clone has 10 kbp sequence gap, which result in 2 contigs
(contig a, b). This sequence shows contig b. The orientation of the
sequence is from SP6 to T7 of the PAC clone. Genes were predicted
from the integrated results of the following:GENSCAN1.0, BLASTN1.4,
BLASTX2.0 as well as SplicePredictor (October:GENSCAN1.0, The
genomic sequence was searched against the non-redundant database
NRP (PIR, SWISSPROT, GENPEPT, PDB) from MAF DNABank and the cDNA
sequence database at RGP. Protein similarities of the coding
regions were searched against NRP with BLASTP2.0. ESTs represent
the identified cDNA sequences using BLASTN1.4 with the
corresponding DBJ accession no. and RGP clone ID.

FEATURES
source
1. 126038
/organism="Oryza sativa (japonica cultivar-group)"
/mol_type="genomic DNA"
/cultivar="Nipponbare"
/db_xref="taxon:39947"
/chromosome="2"

CDS

/clone="PO437H03 (contig b)"
Complement (join(1542..1704,1808..2005,2133..2332,
2428..2541,2732..2868,3006..3116,5410..5541))
/note="Similar to glycogenin glucosyltransferase (EC
2.4.1.186). (297341)"
/codon_start=1
/protein_id="BAA82375.1"
/db_xref="GI:5441877"

CDS

/translation="MKGVYECCEYVAIPDAPQDPDFLRITPLVHNSDIAIYVOA
RMRYNADEICMTMOMESLDYFTVEQVSSVCAFFGFGTAGVRSVAVNAAGW
KDRITVEDMDLAIRASIKMKWEYVIGVYSELPKAFRFOQHWSCGPNLFRK
MLMEIVRNKKVITMKKHIVYIFPLIRKIAHIVTFAFYGLIIPATFVEVNI PKMG
CVYIPITLILNSVTERPSFHLLFNLIFENWMSLHRTKALGLGLEAGANMVAYLE
KGNALMKMKSSSKSASKSEMRVMDRLVTEBLGAAALFSCGWDLAFGDDHFIYLF
FCGAAFFIVIGYVGTIVPOS"
join(9281..9351,11606..11736,12883..12994,13030..13164,
13319..13331)
/note="hypothetical protein"
/codon_start=1
/protein_id="BAA82376.1"
/db_xref="GI:5441878"
/translation="MKKQOQKSIPTMGMDLTNTSLSDPAKKKPSVAOVNCKKFS
OCVQVMEPRVDVEYSLQQLPLIDTFLRCKRGIDELKKTVDLDRKTPVYTTIR
CTGHEAVILLVLRFGSSLSLSLARFARTKVCSSDDDDDDGDESN"
Complement (16578..17255)
/note="ESTs AU070372(513446), AU075541(50353) correspond to
a region of the predicted gene.
Similar to Arabidopsis thaliana BAC genomic sequence.
(AC002292)"
/codon_start=1
/protein_id="BAA82377.1"
/db_xref="GI:5441879"
/translation="MAAPTRAAALSTSTASVTSGKRFITSPFSLSPLATGYRAA
GARAKRSASASTVATTAIGDKLPDATTLSYDDPADGLKTVAELTAGKAAVIFA
VGAFTPTCSQKHLPGFTKAGCLHAKGVDALACVMDAPFARAKESLIGDADVL
LISDGNLELTRALGVEMDLSDKPMGLGVNSRRYALLADGGVAVNLBERGAFITSSA
EEMLKAL"

CDS

Complement (17699..18004)
/note="3' long terminal repeat"
Complement (join(18782..19019,19135..19266,19513..19610,
19855..20113,20190..20488,21053..21389,21495..21645,
22169..22484,22743..22774,23219..24224))
/note="EST C28952(C62945) corresponds to a region of the
predicted gene.
Similar to maize transposon MUDR mudra protein.
(AC003981)"
/codon_start=1
/protein_id="BAA82378.1"
/db_xref="GI:5441880"
/translation="MADEGERVGIIVDEMERSDNEVDSDASDEEGVMAITMAN
EDPSGLVISEGDHVPWEYKENEVLEGAVYAKDKRAVYGMVAISLORREYVSTY
YVEVCEKMEDECDWRVHAAYKGMNDYKRSIVTERKCYIOGVEKRRHRTASFAVSEMY
SSVNNIGEPESIIIRHLENKFKYISVAKMRAROKIEMRYGTFEASDNLPRILA
TIAOSNNNYVDLHFTSVDRKTSVLORAFPSGACINAVHIAVCRPNVCLJHDK
YKQILITAGCCNNNOVLPMAFAPESNTSSWPCSHVLAADCGISPNVVSNF
AEVYNMKGVEECVLKAGSGSTTISAOVYIIPDSKRVKRRORTRINDDESE
REKALFHTWSEETIGFSGSTTISAOVYIIPDSKRVKRRORTRINDDESE
AGAAVDTPLALNRGIDRNHRSLVABEQGLSTPRPRREMLVNDPVMVLEAA
DDDDPAKRWDAEDSLALVDRMRETFPHLPGEMAPTIQDYSYLLGLAGAAV
PYDVGKMEDEITAREQVWRBLPHGPTTTPYSTVSPSKADQALWLTILFVNDIFV
GYDVFPEFRDOPDIWEPYTEBAVAPLADGLSCTSDQAWLTLFVNDIFV
EPICPWRNORGLROVPGVOPVLPLDHSILTPRQDAGLAAVADQYVDDVLA
TEEVINELFPHTEENRDYLRVLPRTARVTFPDADBPVAAVTAATVAPHRDDYF
VAGCGRTSSWGTITASAYARSRSPTGYCFARTSSAFERVRHRRFHLRGGVR
HLGGRVQLFSLSVSPSLRTGPTSPQPDIDHAGADHDVYSSQLGAPFAHTQEQ
FEVTPVQAGVGRVAPPDRLTSHGIRKQGRDKRRRO"

LTR

CDS

CDS

LTR

Complement (25215..25521)
/note="5' long terminal repeat"
join(25810..25825,29004..31165)
/note="Similar to putative receptor kinase. (AC002332)"
/codon_start=1
/protein_id="BAA82379.1"
/db_xref="GI:5441881"

/organism="Apis mellifera"
/mol_type="genomic DNA"
/db_xref="taxon:7460"
/clone="CH224-5703"

BASE COUNT 39316 a 30537 c 30943 g 39489 t 6283 others

ORIGIN

Query Match 76.2%; Score 16; DB 2; Length 146566;
Best Local Similarity 100.0%; Pred. No. 25;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 CGTCGACGTCGAGA 17
Db 135270 CGTCGACGTCGAGA 135255

RESULT 9
AC130730/c 166304 bp DNA linear HTG 14-AUG-2002
LOCUS Oryza sativa (japonica cultivar-group) chromosome 5 clone P0681D04,
DEFINITION *** SEQUENCING IN PROGRESS ***; 6 ordered pieces.
AC130730
AC130730.1 GI:22218364
VERSION HTG; HTGS PHASE2.
KEYWORDS Oryza sativa (japonica cultivar-group)
SOURCE Oryza sativa (japonica cultivar-group)
ORGANISM Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
Eriaraloideae; Oryzoae; Oryza.
1 (bases 1 to 166304)
Chow,T.-Y., Hsing,Y.-I.C., Chen,C.-S., Chen,H.-H., Liu,S.-M.,
Chen,Y.-T., Chang,S.-J., Chen,H.-C., Chen,S.-K., Chen,T.-R.,
Chen,Y.-L., Cheng,C.-H., Chung,C.-I., Han,S.-Y., Hsiao,S.-H.,
Hsiung,J.-N., Hsu,C.-H., Huang,J.-J., Kan,P.-I., Lee,M.-C.,
Leng,H.-L., Li,Y.-P., Lin,S.-J., Lin,Y.-C., Wu,S.-W., Yu,C.-Y.,
Yu,S.-W., Wu,H.-P. and Shaw,J.-F.
Oryza sativa PAC P0681D04 genomic sequence
Unpublished
2 (bases 1 to 166304)
Chow,T.-Y. and Hsing,Y.-I.C.
Direct Submission
Submitted (14-AUG-2002) Institute of Botany, Academia Sinica, 128,
Section 2, Academia Road, Nankang, Taipei 11529, Taiwan
* NOTE: This is a 'working draft' sequence. It currently
* consists of 6 contigs. Gaps between the contigs
* are represented as runs of N. The order of the pieces
* is believed to be correct as given, however the sizes
* of the gaps between them are based on estimates that have
* provided by the submitter.
* This sequence will be replaced
* by the finished sequence as soon as it is available and
* the accession number will be preserved.

1 8678: contig of 8678 bp in length
8679 8778: gap of unknown length
8779 14903: contig of 6125 bp in length
14904 15003: gap of unknown length
15004 35393: contig of 20390 bp in length
35394 35483: gap of unknown length
35484 121324: contig of 85831 bp in length
121325 121424: gap of unknown length
121425 135356: contig of 13932 bp in length
135357 135456: gap of unknown length
135457 166304: contig of 30848 bp in length.
Location/Qualifiers
1.166304
/organism="Oryza sativa (japonica cultivar-group)"
/mol_type="genomic DNA"
/cultivar="Nipponbare"
/db_xref="taxon:39947"
/chromosome="5"
/clone="P0681D04"

BASE COUNT 46182 a 37272 c 36481 g 45869 t 500 others
ORIGIN

Query Match 76.2%; Score 16; DB 2; Length 166304;
Best Local Similarity 100.0%; Pred. No. 25;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5 CGAAGCTTCGAGATGA 20
Db 99712 CGAAGCTTCGAGATGA 99697

RESULT 10
AR268334 22 bp DNA linear PAT 10-APR-2003
LOCUS AR268334
DEFINITION Sequence 19 from patent US 6498148.
ACCESSION AR268334
VERSION AR268334.1 GI:29698684
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
1 (bases 1 to 22)
Raz,E.
Immunization-free methods for treating antigen-stimulated
inflammation in a mammalian host and shifting the host's antigen
immune responsiveness to a Th1 phenotype
Patent: US 6498148-A 19-24-DEC-2002;
Location/Qualifiers
1..22
/organism="unknown"

BASE COUNT 6 a 3 c 7 g 6 t
ORIGIN

Query Match 71.4%; Score 15; DB 6; Length 22;
Best Local Similarity 100.0%; Pred. No. 91;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 6 GAACGTTGAGATGA 20
Db 8 GAACGTTGAGATGA 22

RESULT 11
AR287741 22 bp DNA linear PAT 12-JUN-2003
LOCUS AR287741
DEFINITION Sequence 1 from patent US 6534062.
ACCESSION AR287741
VERSION AR287741.1 GI:31674761
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
1 (bases 1 to 22)
Raz,E., Cho,H.-J., Richman,D. and Horner,A.A.
Methods for increasing a cytotoxic T lymphocyte response in vivo
Patent: US 6534062-A 18-MAR-2003;
Location/Qualifiers
1..22
/organism="unknown"

BASE COUNT 6 a 3 c 7 g 6 t
ORIGIN

Query Match 71.4%; Score 15; DB 6; Length 22;
Best Local Similarity 100.0%; Pred. No. 91;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 6 GAACGTTGAGATGA 20
Db 8 GAACGTTGAGATGA 22

RESULT 12
AR287743 22 bp DNA linear PAT 12-JUN-2003
LOCUS AR287743

DEFINITION Sequence 3 from patent US 6534062.
ACCESSION AR287743
VERSION AR287743.1 GI:31674763
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
1 (bases 1 to 22)
AUTHORS Raz,E., Cho,H.J., Richman,D. and Horner,A.A.
TITLE Methods for increasing a cytotoxic T lymphocyte response in vivo
JOURNAL Patent: US 6534062-A 3 18-MAR-2003;
FEATURES Location/Qualifiers
source 1..22
/organism="unknown"
BASE COUNT 6 a 3 c 7 g 6 t
ORIGIN
Query Match 71.4%; Score 15; DB 6; Length 22;
Best Local Similarity 100.0%; Pred. No. 91;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 6 GAACGTCGAGATGA 20
Db 8 GAACGTCGAGATGA 22
RESULT 13
AR308057 22 bp DNA linear PAT 12-JUN-2003
LOCUS Sequence 1 from patent US 6552006.
ACCESSION AR308057
VERSION AR308057.1 GI:31698950
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
1 (bases 1 to 22)
AUTHORS Raz,E., Kornbluth,R., Catanzaro,A., Hayashi,T. and Carson,D.
TITLE Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen
JOURNAL Patent: US 6552006-A 1 22-APR-2003;
FEATURES Location/Qualifiers
source 1..22
/organism="unknown"
BASE COUNT 6 a 3 c 7 g 6 t
ORIGIN
Query Match 71.4%; Score 15; DB 6; Length 22;
Best Local Similarity 100.0%; Pred. No. 91;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 6 GAACGTCGAGATGA 20
Db 8 GAACGTCGAGATGA 22
RESULT 14
AX036945 22 bp DNA linear PAT 16-NOV-2000
LOCUS Sequence 2 from Patent FR2790955.
ACCESSION AX036945
VERSION AX036945.1 GI:11226373
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Carpentier,A.
JOURNAL Patent: FR 2790955-A 2 22-SEP-2000;
FEATURES Assist Publ. HOPIAUX DE PARIS (FR)
Location/Qualifiers
source 1..22
/organism="synthetic construct"

/mol_type="genomic DNA"
/db_xref="taxon:32630"
/note="Oligodeoxynucleotide"
BASE COUNT 6 a 3 c 7 g 6 t
ORIGIN
Query Match 71.4%; Score 15; DB 6; Length 22;
Best Local Similarity 100.0%; Pred. No. 91;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 6 GAACGTCGAGATGA 20
Db 8 GAACGTCGAGATGA 22
RESULT 15
AX046993 22 bp DNA linear PAT 15-DEC-2000
LOCUS Sequence 2 from Patent WO0067787.
ACCESSION AX046993
VERSION AX046993.1 GI:11876420
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Moss,R.B.
TITLE Hiv immunogenic compositions and methods
JOURNAL Patent: WO 0067787-A 2 16-NOV-2000;
FEATURES THE IMMUNE RESPONSE CORPORATION (US)
Location/Qualifiers
source 1..22
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
/note="phosphorothioate-modified synthetic oligodeoxynucleotide"
BASE COUNT 6 a 3 c 7 g 6 t
ORIGIN
Query Match 71.4%; Score 15; DB 6; Length 22;
Best Local Similarity 100.0%; Pred. No. 91;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 6 GAACGTCGAGATGA 20
Db 8 GAACGTCGAGATGA 22
Search completed: December 19, 2003, 13:18:52
Job time : 1199 secs

This Page Blank (uspto.gov)

DR WPI; 2002-657426/70.

XX Immunomodulatory polynucleotide for modulating an immune response in a
PT subject suffering from disorders associated with Th2-type immune
PT response, e.g. allergy, or infectious disease, comprises an
PT immunostimulatory sequence -

PS Claim 4; Page 21; 95pp; English.

XX The present invention describes an immunomodulatory polynucleotide (1)
CC comprising an immunostimulatory sequence (ISS). Also described: (1) an
CC immunomodulatory composition comprising (1); (2) an immunomodulatory
CC polynucleotide/microcarrier (IMP/MC) complex, comprising (1) linked to a
CC biodegradable MC, where the MC is less than 10 micrometre in size; and
CC (3) a kit comprising (1). (1) has anti-allergic, antiasthmatic, virucide,
CC antibacterial and protozoacide activities, and can be used as a modulator
CC of immune response. (1) is useful for modulating an immune response in an
CC individual suffering from disorders associated with a Th2-type immune
CC response, especially an allergy or asthma, or an infectious disease. (1)
CC is also useful for increasing interferon-gamma (IFN-gamma) in an
CC individual having idiopathic pulmonary fibrosis, or IFN-alpha in an
CC individual having a viral infection. (1) is further useful for
CC ameliorating a symptom of an infectious disease caused by a cellular
CC pathogen such as mycobacterial disease, malaria, leishmaniasis,
CC toxoplasmosis, schistosomiasis and clonorchiasis in an individual, or a
CC symptom of an immunoglobulin E (IgE)-related disorder, preferably an
CC allergy-related disorder, in particular asthma in an individual. The
CC present sequence represents an immunomodulatory oligonucleotide from
CC the present invention.

XX Sequence 21 BP; 5 A; 4 C; 6 G; 6 T; 0 other;

SO Query Match 100.0%; Score 21; DB 24; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.0064;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 TCGTGAACGTCGAGATGAT 21
Db 1 TCGTGAACGTCGAGATGAT 21

RESULT 2
ABQ75170
ID ABQ75170 standard; DNA; 19 BP.
XX
AC ABQ75170;
XX
DT 05-NOV-2002 (first entry)
XX
DE ISS immunomodulatory oligonucleotide SEQ ID NO:19.
XX
XX Immunostimulatory sequence; ISS: immunomodulatory; immune response;
KW allergy; asthma; infectious disease; interferon-gamma; IFN-gamma;
KW idiopathic pulmonary fibrosis; viral infection; mycobacterial disease;
KW malaria; leishmaniasis; toxoplasmosis; schistosomiasis; clonorchiasis;
KW immunoglobulin E; IgE-related disorder; anti-allergic; antiasthmatic;
KW virucide; antibacterial; protozoacide; ss.
XX
OS Synthetic.
XX
PN WO200252002-A2.
XX
PD 04-JUL-2002.
XX
PF 27-DEC-2001; 2001WO-US50821.
XX
PR 27-DEC-2000; 2000US-258675P.
XX
PA (DYNA-) DYNAVAX TECHNOLOGIES CORP.
XX
PI Fearon KL, Dina D;
XX
DR WPI; 2002-657426/70.

XX Immunomodulatory polynucleotide for modulating an immune response in a
PT subject suffering from disorders associated with Th2-type immune
PT response, e.g. allergy, or infectious disease, comprises an
PT immunostimulatory sequence -

PS Claim 4; Page 20; 95pp; English.

XX The present invention describes an immunomodulatory polynucleotide (1)
CC comprising an immunostimulatory sequence (ISS). Also described: (1) an
CC immunomodulatory composition comprising (1); (2) an immunomodulatory
CC polynucleotide/microcarrier (IMP/MC) complex, comprising (1) linked to a
CC biodegradable MC, where the MC is less than 10 micrometre in size; and
CC (3) a kit comprising (1). (1) has anti-allergic, antiasthmatic, virucide,
CC antibacterial and protozoacide activities, and can be used as a modulator
CC of immune response. (1) is useful for modulating an immune response in an
CC individual suffering from disorders associated with a Th2-type immune
CC response, especially an allergy or asthma, or an infectious disease. (1)
CC is also useful for increasing interferon-gamma (IFN-gamma) in an
CC individual having idiopathic pulmonary fibrosis, or IFN-alpha in an
CC individual having a viral infection. (1) is further useful for
CC ameliorating a symptom of an infectious disease caused by a cellular
CC pathogen such as mycobacterial disease, malaria, leishmaniasis,
CC toxoplasmosis, schistosomiasis and clonorchiasis in an individual, or a
CC symptom of an immunoglobulin E (IgE)-related disorder, preferably an
CC allergy-related disorder, in particular asthma in an individual. The
CC present sequence represents an immunomodulatory oligonucleotide from
CC the present invention.

XX Sequence 19 BP; 4 A; 4 C; 6 G; 5 T; 0 other;

SO Query Match 90.5%; Score 19; DB 24; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.092;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 TCGTGAACGTCGAGATG 19
Db 1 TCGTGAACGTCGAGATG 19

RESULT 3
ABQ75181
ID ABQ75181 standard; DNA; 22 BP.
XX
AC ABQ75181;
XX
DT 05-NOV-2002 (first entry)
XX
DE ISS immunomodulatory oligonucleotide SEQ ID NO:30.
XX
XX Immunostimulatory sequence; ISS: immunomodulatory; immune response;
KW allergy; asthma; infectious disease; interferon-gamma; IFN-gamma;
KW idiopathic pulmonary fibrosis; viral infection; mycobacterial disease;
KW malaria; leishmaniasis; toxoplasmosis; schistosomiasis; clonorchiasis;
KW immunoglobulin E; IgE-related disorder; anti-allergic; antiasthmatic;
KW virucide; antibacterial; protozoacide; ss.
XX
OS Synthetic.
XX
PN WO200252002-A2.
XX
PD 04-JUL-2002.
XX
PF 27-DEC-2001; 2001WO-US50821.
XX
PR 27-DEC-2000; 2000US-258675P.
XX
PA (DYNA-) DYNAVAX TECHNOLOGIES CORP.
XX
PI Fearon KL, Dina D;
XX
DR WPI; 2002-657426/70.

PT Immunomodulatory polynucleotide for modulating an immune response in a
PT subject suffering from disorders associated with Th2-type immune
PT response, e.g. allergy, or infectious disease, comprises an
PT immunostimulatory sequence -
XX
XX
PS Disclosure; Page 21; 95pp; English.
XX
XX The present invention describes an immunomodulatory polynucleotide (1)
CC comprising an immunostimulatory sequence (ISS). Also described: (1) an
CC immunomodulatory composition comprising (1); (2) an immunomodulatory
CC polynucleotide/microcarrier (IMP/MC) complex, comprising (1) linked to a
CC biodegradable MC, where the MC is less than 10 micrometre in size; and
CC (3) a kit comprising (1). (1) has anti-allergic, antiasthmatic, virucide,
CC antibacterial and protozoacide activities, and can be used as a modulator
CC of immune response. (1) is useful for modulating an immune response in an
CC individual suffering from disorders associated with a Th2-type immune
CC response, especially an allergy or asthma, or an infectious disease. (1)
CC is also useful for increasing interferon-gamma (IFN-gamma) in an
CC individual having idiopathic pulmonary fibrosis, or IFN-alpha in an
CC individual having a viral infection. (1) is further useful for
CC ameliorating a symptom of an infectious disease caused by a cellular
CC pathogen such as mycobacterial disease, malaria, leishmaniasis,
CC toxoplasmosis, schistosomiasis and clonorchiasis in an individual, or a
CC symptom of an immunoglobulin E (IgE)-related disorder, preferably an
CC allergy-related disorder, in particular asthma in an individual. The
CC present sequence represents an immunomodulatory oligonucleotide from
CC the present invention.
XX
SQ Sequence 22 BP; 5 A; 4 C; 7 G; 6 T; 0 other;
Query Match 90.5%; Score 19; DB 24; Length 22;
Best Local Similarity 100.0%; Pred. No. 0.091;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 TCCTCGACGTTGAGATG 19
DB 4 TCCTCGACGTTGAGATG 22
RESULT 4
ABQ75165
ID ABQ75165 standard; DNA; 18 BP.
XX
XX ABQ75165;
AC
XX
DT 05-NOV-2002 (first entry)
XX
DE ISS immunomodulatory oligonucleotide SEQ ID NO:14.
XX
XX Immunostimulatory sequence; ISS: immunomodulatory; immune response;
KW allergy; asthma; infectious disease; interferon-gamma; IFN-gamma;
KW idiopathic pulmonary fibrosis; viral infection; mycobacterial disease;
KW malaria; leishmaniasis; toxoplasmosis; schistosomiasis; clonorchiasis;
KW immunoglobulin E; IgE-related disorder; anti-allergic; antiasthmatic;
KW virucide; antibacterial; protozoacide; ss.
XX
XX Synthetic.
OS
XX
PN WO200252002-A2.
XX
PD 04-JUL-2002.
XX
PF 27-DEC-2001; 2001WO-US50821.
XX
PR 27-DEC-2000; 2000US-258675P.
XX
PA (DYNA-) DYNAVAX TECHNOLOGIES CORP.
XX
PI Fearon KL, Dina D;
XX
DR WPI; 2002-657426/70.
XX
PT Immunomodulatory polynucleotide for modulating an immune response in a

PT subject suffering from disorders associated with Th2-type immune
PT response, e.g. allergy, or infectious disease, comprises an
PT immunostimulatory sequence -
XX
XX
PS Example 1; Page 20; 95pp; English.
XX
XX The present invention describes an immunomodulatory polynucleotide (1)
CC comprising an immunostimulatory sequence (ISS). Also described: (1) an
CC immunomodulatory composition comprising (1); (2) an immunomodulatory
CC polynucleotide/microcarrier (IMP/MC) complex, comprising (1) linked to a
CC biodegradable MC, where the MC is less than 10 micrometre in size; and
CC (3) a kit comprising (1). (1) has anti-allergic, antiasthmatic, virucide,
CC antibacterial and protozoacide activities, and can be used as a modulator
CC of immune response. (1) is useful for modulating an immune response in an
CC individual suffering from disorders associated with a Th2-type immune
CC response, especially an allergy or asthma, or an infectious disease. (1)
CC is also useful for increasing interferon-gamma (IFN-gamma) in an
CC individual having idiopathic pulmonary fibrosis, or IFN-alpha in an
CC individual having a viral infection. (1) is further useful for
CC ameliorating a symptom of an infectious disease caused by a cellular
CC pathogen such as mycobacterial disease, malaria, leishmaniasis,
CC toxoplasmosis, schistosomiasis and clonorchiasis in an individual, or a
CC symptom of an immunoglobulin E (IgE)-related disorder, preferably an
CC allergy-related disorder, in particular asthma in an individual. The
CC present sequence represents an immunomodulatory oligonucleotide from
CC the present invention.
XX
SQ Sequence 18 BP; 4 A; 4 C; 5 G; 5 T; 0 other;
Query Match 76.2%; Score 16; DB 24; Length 18;
Best Local Similarity 100.0%; Pred. No. 5;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 4 TCGACGTTGAGATG 19
DB 3 TCGACGTTGAGATG 18
RESULT 5
AAD24905
ID AAD24905 standard; DNA; 20 BP.
XX
XX AAD24905;
AC
XX
DT 12-MAR-2002 (first entry)
XX
DE Double-stranded immunostimulatory oligodeoxynucleotide (ISS-ODN).
XX
XX Cell death; DNA damage; DNA-dependent protein kinase; DNA-PK; necrosis;
KW immune response; apoptosis; Alzheimer's disease; Parkinson's disease;
KW rheumatoid arthritis; inflammation; osteoporosis; myocardial infarction;
KW liver disease; reperfusion injury; carcinoma; multiple sclerosis; stroke;
KW amyotrophic lateral sclerosis; Acquired Immune Deficiency Syndrome; AIDS;
KW head injury damage; aplastic anaemia; tumour; organ transplantation;
KW cerebral infarction; follicular lymphoma; systemic lupus erythematosus;
KW viral infection; glomerulonephritis; apoptosis; autoimmune disorder;
KW sepsis; immunostimulatory oligodeoxynucleotide; ISS-ODN; ds.
XX
XX Unidentified.
OS
XX
PN WO200185910-A2.
XX
PD 15-NOV-2001.
XX
PF 04-MAY-2001; 2001WO-US14508.
XX
PR 05-MAY-2000; 2000US-202274P.
XX
PR 17-JAN-2001; 2001US-262321P.
XX
PA (REGC) UNIV CALIFORNIA.
XX
PI Raz E, Lois AF, Takabayashi K;
XX

DR WPI; 2002-062244/08.

XX Modulating cell death or reducing DNA damage in eukaryotic cells,
 PT useful for reducing cell death in individual or organ, comprises
 PT contacting cell with agent modulating biological activity of
 PT DNA-dependent protein kinase

PS Example 1; Page 31; 57pp; English.

XX The invention relates to a method for modulating cell death or reducing
 CC DNA damage in an eukaryotic cell by contacting the cell with an agent
 CC that modulates the biological activity of DNA-dependent protein kinase
 CC (DNA-PK). The invention also relates nucleic acids which modulate the
 CC immune response binding to Ku antigen, resulting in activation of DNA-PK.
 CC The method is useful for modulating cell death or reducing DNA damage in
 CC an eukaryotic cell, for treating any disorder resulting from a genotoxic
 CC insert to a cell e.g., necrosis, apoptosis. The method is also useful
 CC for treating cell death-related indications such as Alzheimer's disease,
 CC Parkinson's disease, rheumatoid arthritis, septic shock, stroke,
 CC central nervous system inflammation, osteoporosis, degenerative liver
 CC disease, cerebellar degeneration, reperfusion injury, multiple sclerosis,
 CC amyotrophic lateral sclerosis, myocardial infarction, head injury damage,
 CC acquired immunodeficiency syndrome (AIDS), aplastic anaemia, cerebral
 CC infarction, bypass heart surgery, organ transplantation. The method is
 CC also useful for treating follicular lymphomas, carcinomas, autoimmune
 CC disorders (systemic lupus erythematosus), hormone dependent tumours,
 CC immune mediated glomerulonephritis, apoptosis and viral infections. The
 CC present sequence is immunostimulatory oligodeoxynucleotide (ISS-ODN)
 CC used for identifying ISS-binding protein, which is used in the
 CC exemplification of the invention.

XX Sequence 20 BP; 6 A; 3 C; 6 G; 5 T; 0 other;

QQ Query_Match 71.4%; Score 15; DB 24; Length 20;
 Best Local Similarity 100.0%; Pred. No. 19;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 6 GAACGTCGAGATGA 20
 Db 6 GAACGTCGAGATGA 20

RESULT 6
 AAV32079
 ID AAV32079 standard; DNA; 22 BP.

XX AAV32079;

AC 09-SEP-1998 (first entry)

XX Nucleotide sequence of DY1018.

DE DY1018; beta-gal; ISS-PN/IMM; antigen; immune response; antibody;
 XX immunisation; anapylaxis; IGE; retinopathies; ss.

XX synthetic.

OS Key Location/Qualifiers
 PH modified_base 1..22
 FT /*tag= a
 FT /note= "phosphothioate backbone"

XX WO9816247-A1.
 PN 23-APR-1998.
 PD 09-OCT-1997; 97WO-US19004.
 PF 11-OCT-1996; 96US-0028118.
 PR (REGC) UNIV CALIFORNIA.
 PA Carson DA, Raz E, Roman M;
 XX PI

XX WPI; 1998-261028/23.

XX New immunomodulatory compositions - comprising an antigen conjugated
 PT to a polynucleotide that contains an immunostimulatory sequence

PS Example 1; Page 36; 69pp; English.

XX This is the nucleotide sequence of DY1018, which is conjugated to
 CC beta-gal to form ISS-PN/IMM, comprising an immunomodulatory molecule
 CC (IMM), which comprises an antigen conjugated to a polynucleotide
 CC (PN) that contains at least one immunostimulatory nucleotide sequence
 CC (ISS). The conjugate synergistically boost the magnitude of the host
 CC immune response against an antigen to a level greater than the host
 CC immune response to either the IMM, antigen or ISS-PN alone. These
 CC responses to ISS-PN/IMM conjugates are particularly acute during
 CC the important early phase of the host immune response to an antigen.
 CC The ISS-PN/IMM conjugates boost both humoral (antibody) and cellular
 CC (Th1 type) immune responses of the host. Thus, use of the method to
 CC boost the immune responsiveness of a host to subsequent challenge by a
 CC sensitising antigen without immunisation avoids the risk of
 CC Th2-mediated, immunisation-induced anaphylaxis by suppressing IGE
 CC production in response to the antigen challenge. The conjugates can
 CC also be used to combat pathogenic infection and to stimulate
 CC therapeutic angiogenesis to treat conditions in which localised blood
 CC flow plays a significant etiological role, e.g. retinopathies.

XX Sequence 22 BP; 6 A; 3 C; 7 G; 6 T; 0 other;

QQ Query_Match 71.4%; Score 15; DB 19; Length 22;
 Best Local Similarity 100.0%; Pred. No. 19;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 6 GAACGTCGAGATGA 20
 Db 8 GAACGTCGAGATGA 22

RESULT 7
 AAX36624
 ID AAX36624 standard; DNA; 22 BP.

XX AAX36624;

AC 09-JUL-1999 (first entry)

XX ISS-ODN DY1018 nucleotide sequence.

DE Antigen-stimulated inflammation; immunostimulatory oligonucleotide;
 XX granulocyte-mediated tissue inflammation; Th2 type immune response;
 KW immune responsiveness modulation; idiopathic hyperesinophilic syndrome;
 KW cutaneous basophil hypersensitivity; ISS-ODN; asthma; nasal polyps;
 KW allergic rhinitis; atopic dermatitis; allergic conjunctivitis;
 KW eosinophilic fasciitis; therapy; ss.

XX synthetic.

OS Key Location/Qualifiers
 PH modified_base 1..22
 FT /*tag= a
 FT /note= "phosphothioate backbone"

XX WO9911275-A2.
 PN 11-MAR-1999.
 PD 04-SEP-1998; 98WO-US18382.
 PF 05-SEP-1997; 97US-0927120.
 PR (REGC) UNIV CALIFORNIA.
 PA Ray E;
 XX PI
 XX WPI; 1999-312404/26.
 DR Reducing antigen-stimulated granulocyte-mediated inflammation
 XX PT

PS Example 2; Page 30; 63pp; English.
XX This is the ISS-ODN DV1018 nucleotide sequence.
CC The invention relates to a method for preventing or reducing
CC antigen-stimulated, granulocyte-mediated tissue inflammation in a mammal,
CC by administering an immunostimulatory oligonucleotide (ISS-ODN), where:
CC (a) reduction in, or the absence of, a Th2 type immune response is
CC measured; or (b) there is a reduction or absence of other clinical signs
CC of inflammation in the host after antigen challenge. The method is used
CC to reduce or suppress granulocyte-mediated inflammation in a host tissue,
CC and to modulate the host's immune responsiveness to an antigen,
CC particularly where the subject suffers from asthma, nasal polyposis,
CC allergic rhinitis, atopic dermatitis, allergic conjunctivitis,
CC eosinophilic fasciitis, idiopathic hypereosinophilic syndrome, or
CC cutaneous basophil hypersensitivity. Unlike prior art treatment by
CC antigen immunization, the method is an antigen-independent method,
CC and avoids host production of both interleukin-4 (IL-4), which carries
CC risk of anaphylaxis, and IL-5 which actually encourages granulocyte
CC adhesion to endothelia.
XX
SQ Sequence 22 BP; 6 A; 3 C; 7 G; 6 T; 0 other;
Query Match 71.4%; Score 15; DB 20; Length 22;
Best Local Similarity 100.0%; Pred. No. 19;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 6 GAACGTTTCGAGATGA 20
DB 8 GAACGTTTCGAGATGA 22
RESULT 8
AAV80105/c
ID AAV80105 standard; DNA; 22 BP.
XX
XX AAV80105;
AC
XX
XX 12-MAR-1999 (first entry)
DT
XX
XX
DE Oligo used in experiments for stimulation of cytokine production.
XX
XX Immunomodulatory; immunostimulatory; octanucleotide; immune regulation;
XX ISS: cancer; allergy; asthma; hepatitis B infection; papillomavirus;
XX human immunodeficiency virus; influenza; herpes; M. tuberculosis; ss;
XX B. pertussis; malaria; plasmodia; leishmania; Trypanosoma; Schistosoma.
OS Synthetic.
XX
XX WO9855495-A2.
PN
XX
XX 10-DEC-1998.
PD
XX
XX 05-JUN-1998; 98WO-US11578.
PF
XX
XX 06-JUN-1997; 97US-0048793.
PR
XX
XX (DYNA-) DYNAVAX TECHNOLOGIES CORP.
PA
XX
XX Dina D, Roman M, Schwartz D;
PI
XX
XX WPI; 1999-059898/05.
DR
XX
XX Immunostimulatory oligonucleotides regulate the immune system - and
PT contain an immune-stimulating octanucleotide sequence; for treating
PT cancer, allergic and infectious diseases
XX
XX Example 1; Page 29; 63pp; English.
PS
XX
XX The invention relates to immunomodulatory oligonucleotides that comprise
CC at least 1 immunostimulatory octanucleotide sequence (ISS) where the ISS
CC sequences are selected from the group consisting of AACGTTCC, AACGTTCCG,
CC GACGTTCC, and GACGTTCC. The immunomodulatory sequences are used to treat
CC patients needing immune regulation, such as those suffering from cancer,
CC an allergic disease and asthma. They are also used to prevent infectious
CC diseases such as influenza, herpes, hepatitis B, human immunodeficiency
CC and papillomavirus, Hemophilus influenza, Mycobacterium tuberculosis and
CC Bordetella pertussis, malarial plasmodia, Leishmania, Trypanosoma and
CC Schistosoma. The immunomodulatory sequences are used to screen for human
CC immunostimulatory activity by incubating macrophage cells and the
CC oligonucleotide; and determining the relative amount of Th1-biased
CC cytokines in the supernatant. Sequences AAV80104 to AAV80116 represent
CC oligonucleotides that were tested for immunostimulatory activity. These
CC were used in experiments for the stimulation of cytokine production and
CC were found to lack immunostimulatory activity. The invention provides
CC specific claimed examples (AAV80096-103) of immunomodulatory sequences.
XX
SQ Sequence 22 BP; 5 A; 7 C; 4 G; 6 T; 0 other;
Query Match 71.4%; Score 15; DB 20; Length 22;
Best Local Similarity 100.0%; Pred. No. 19;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 6 GAACGTTTCGAGATGA 20
DB 15 GAACGTTTCGAGATGA 1
RESULT 9
AAV80096
ID AAV80096 standard; DNA; 22 BP.
XX
XX AAV80096;
AC
XX
XX 12-MAR-1999 (first entry)
DT
XX
XX
DE Immunomodulatory oligo comprising an ISS sequence.
XX
XX Immunomodulatory; immunostimulatory; octanucleotide; immune regulation;
XX ISS: cancer; allergy; asthma; hepatitis B infection; papillomavirus;
XX human immunodeficiency virus; influenza; herpes; M. tuberculosis; ss;
XX B. pertussis; malaria; plasmodia; leishmania; Trypanosoma; Schistosoma.
OS Synthetic.
XX
XX WO9855495-A2.
PN
XX
XX 10-DEC-1998.
PD
XX
XX 05-JUN-1998; 98WO-US11578.
PF
XX
XX 06-JUN-1997; 97US-0048793.
PR
XX
XX (DYNA-) DYNAVAX TECHNOLOGIES CORP.
PA
XX
XX Dina D, Roman M, Schwartz D;
PI
XX
XX WPI; 1999-059898/05.
DR
XX
XX Immunostimulatory oligonucleotides regulate the immune system - and
PT contain an immune-stimulating octanucleotide sequence; for treating
PT cancer, allergic and infectious diseases
XX
XX Claim 7; Page 29; 63pp; English.
PS
XX
XX The invention relates to immunomodulatory oligonucleotides that comprise
CC at least 1 immunostimulatory octanucleotide sequence (ISS) where the ISS
CC sequences are selected from the group consisting of AACGTTCC, AACGTTCCG,
CC GACGTTCC, and GACGTTCC. The immunomodulatory sequences are used to treat
CC patients needing immune regulation, such as those suffering from cancer,
CC an allergic disease and asthma. They are also used to prevent infectious
CC diseases such as influenza, herpes, hepatitis B, human immunodeficiency
CC and papillomavirus, Hemophilus influenza, Mycobacterium tuberculosis and
CC Bordetella pertussis, malarial plasmodia, Leishmania, Trypanosoma and
CC Schistosoma. The immunomodulatory sequences are used to screen for human
CC immunostimulatory activity by incubating macrophage cells and the
CC oligonucleotide; and determining the relative amount of Th1-biased

CC an allergic disease and asthma. They are also used to prevent infectious
CC diseases such as influenza, herpes, hepatitis B, human immunodeficiency
CC and papillomavirus, Hemophilus influenza, Mycobacterium tuberculosis and
CC Bordetella pertussis, malarial plasmodia, Leishmania, Trypanosoma and
CC Schistosoma. The immunomodulatory sequences are used to screen for human
CC immunostimulatory activity by incubating macrophage cells and the
CC oligonucleotide; and determining the relative amount of Th1-biased
CC cytokines in the supernatant. Sequences AAV80104 to AAV80116 represent
CC oligonucleotides that were tested for immunostimulatory activity. These
CC were used in experiments for the stimulation of cytokine production and
CC were found to lack immunostimulatory activity. The invention provides
CC specific claimed examples (AAV80096-103) of immunomodulatory sequences.
XX
SQ Sequence 22 BP; 5 A; 7 C; 4 G; 6 T; 0 other;
Query Match 71.4%; Score 15; DB 20; Length 22;
Best Local Similarity 100.0%; Pred. No. 19;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 6 GAACGTTTCGAGATGA 20
DB 15 GAACGTTTCGAGATGA 1
RESULT 9
AAV80096
ID AAV80096 standard; DNA; 22 BP.
XX
XX AAV80096;
AC
XX
XX 12-MAR-1999 (first entry)
DT
XX
XX
DE Immunomodulatory oligo comprising an ISS sequence.
XX
XX Immunomodulatory; immunostimulatory; octanucleotide; immune regulation;
XX ISS: cancer; allergy; asthma; hepatitis B infection; papillomavirus;
XX human immunodeficiency virus; influenza; herpes; M. tuberculosis; ss;
XX B. pertussis; malaria; plasmodia; leishmania; Trypanosoma; Schistosoma.
OS Synthetic.
XX
XX WO9855495-A2.
PN
XX
XX 10-DEC-1998.
PD
XX
XX 05-JUN-1998; 98WO-US11578.
PF
XX
XX 06-JUN-1997; 97US-0048793.
PR
XX
XX (DYNA-) DYNAVAX TECHNOLOGIES CORP.
PA
XX
XX Dina D, Roman M, Schwartz D;
PI
XX
XX WPI; 1999-059898/05.
DR
XX
XX Immunostimulatory oligonucleotides regulate the immune system - and
PT contain an immune-stimulating octanucleotide sequence; for treating
PT cancer, allergic and infectious diseases
XX
XX Claim 7; Page 29; 63pp; English.
PS
XX
XX The invention relates to immunomodulatory oligonucleotides that comprise
CC at least 1 immunostimulatory octanucleotide sequence (ISS) where the ISS
CC sequences are selected from the group consisting of AACGTTCC, AACGTTCCG,
CC GACGTTCC, and GACGTTCC. The immunomodulatory sequences are used to treat
CC patients needing immune regulation, such as those suffering from cancer,
CC an allergic disease and asthma. They are also used to prevent infectious
CC diseases such as influenza, herpes, hepatitis B, human immunodeficiency
CC and papillomavirus, Hemophilus influenza, Mycobacterium tuberculosis and
CC Bordetella pertussis, malarial plasmodia, Leishmania, Trypanosoma and
CC Schistosoma. The immunomodulatory sequences are used to screen for human
CC immunostimulatory activity by incubating macrophage cells and the
CC oligonucleotide; and determining the relative amount of Th1-biased

```
CC cytokines in the supernatant. Sequences AAV80096 to AAV80103 represent
CC specific claimed examples of such immunomodulatory oligonucleotides.
XX
SQ Sequence 22 BP; 6 A; 4 C; 7 G; 5 T; 0 other;

Query Match 71.4%; Score 15; DB 20; Length 22;
Best Local Similarity 100.0%; Pred. No. 19;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 6 GAACGTTGAGATGA 20
Db 8 GAACGTTGAGATGA 22

RESULT 10
AAV80097
ID AAV80097 standard; DNA; 22 BP.
XX
AC AAV80097;
XX
XX 12-MAR-1999 (first entry)
XX
DE Immunomodulatory oligo comprising an ISS sequence.
XX
KW Immunomodulatory; immunostimulatory; octanucleotide; immune regulation;
KW ISS: cancer; allergy; asthma; hepatitis B infection; papillomavirus;
KW human immunodeficiency virus; influenza; herpes; M. tuberculosis; ss;
KW B. pertussis; malaria; plasmodia; Leishmania; Trypanosoma; Schistosoma.
XX
OS Synthetic.
XX
XX WO985495-A2.
XX
XX 10-DEC-1998.
XX
XX 05-JUN-1998; 98WO-US11578.
XX
XX 06-JUN-1997; 97US-0048793.
XX
PA (DYNA-) DYNAVAX TECHNOLOGIES CORP.
XX
PI Dina D, Roman M, Schwartz D;
XX
XX WPI; 1999-059898/05.
XX
XX Immunostimulatory oligonucleotides regulate the immune system - and
XX contain an immune-stimulating octanucleotide sequence; for treating
XX cancer, allergic and infectious diseases
XX
XX Claim 5; Page 29; 63pp; English.
XX
XX The invention relates to immunomodulatory oligonucleotides that comprise
XX at least 1 immunostimulatory octanucleotide sequence (ISS) where the ISS
XX sequences are selected from the group consisting of AACGTTCC, AACGTTGC,
XX GACGTTCC, and GACGTTGC. The immunomodulatory sequences are used to treat
XX patients needing immune regulation, such as those suffering from cancer,
XX an allergic disease and asthma. They are also used to prevent infectious
XX diseases such as influenza, herpes, hepatitis B, human immunodeficiency
XX and papillomavirus, Hemophilus influenza, Mycobacterium tuberculosis and
XX Bordetella pertussis, malarial plasmodia, Leishmania, Trypanosoma and
XX Schistosoma. The immunomodulatory sequences are used to screen for human
XX immunostimulatory activity by incubating macrophage cells and the
XX oligonucleotide; and determining the relative amount of Th1-biased
XX cytokines in the supernatant. Sequences AAV80096 to AAV80103 represent
XX specific claimed examples of such immunomodulatory oligonucleotides.
XX
SQ Sequence 22 BP; 6 A; 3 C; 7 G; 6 T; 0 other;

Query Match 71.4%; Score 15; DB 20; Length 22;
Best Local Similarity 100.0%; Pred. No. 19;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 6 GAACGTTGAGATGA 20
Db 8 GAACGTTGAGATGA 22
```

```
Db 8 GAACGTTGAGATGA 22

RESULT 11
AAV80102
ID AAV80102 standard; DNA; 22 BP.
XX
XX AAV80102;
XX
XX 12-MAR-1999 (first entry)
XX
DE Immunomodulatory oligo comprising an ISS sequence.
XX
XX Immunomodulatory; immunostimulatory; octanucleotide; immune regulation;
XX ISS: cancer; allergy; asthma; hepatitis B infection; papillomavirus;
XX human immunodeficiency virus; influenza; herpes; M. tuberculosis; ss;
XX B. pertussis; malaria; plasmodia; Leishmania; Trypanosoma; Schistosoma.
XX
OS Synthetic.
XX
XX Key Location/Qualifiers
XX modified_base 11
XX FT /*tag= a
XX FT /note= "5-bromocytosine"
XX
XX WO985495-A2.
XX
XX 10-DEC-1998.
XX
XX 05-JUN-1998; 98WO-US11578.
XX
XX 06-JUN-1997; 97US-0048793.
XX
PA (DYNA-) DYNAVAX TECHNOLOGIES CORP.
XX
PI Dina D, Roman M, Schwartz D;
XX
XX WPI; 1999-059898/05.
XX
XX Immunostimulatory oligonucleotides regulate the immune system - and
XX contain an immune-stimulating octanucleotide sequence; for treating
XX cancer, allergic and infectious diseases
XX
XX Claim 23; Page 30; 63pp; English.
XX
XX The invention relates to immunomodulatory oligonucleotides that comprise
XX at least 1 immunostimulatory octanucleotide sequence (ISS) where the ISS
XX sequences are selected from the group consisting of AACGTTCC, AACGTTGC,
XX GACGTTCC, and GACGTTGC. The immunomodulatory sequences are used to treat
XX patients needing immune regulation, such as those suffering from cancer,
XX an allergic disease and asthma. They are also used to prevent infectious
XX diseases such as influenza, herpes, hepatitis B, human immunodeficiency
XX and papillomavirus, Hemophilus influenza, Mycobacterium tuberculosis and
XX Bordetella pertussis, malarial plasmodia, Leishmania, Trypanosoma and
XX Schistosoma. The immunomodulatory sequences are used to screen for human
XX immunostimulatory activity by incubating macrophage cells and the
XX oligonucleotide; and determining the relative amount of Th1-biased
XX cytokines in the supernatant. Sequences AAV80096 to AAV80103 represent
XX specific claimed examples of such immunomodulatory oligonucleotides.
XX
SQ Sequence 22 BP; 6 A; 3 C; 7 G; 6 T; 0 other;

Query Match 71.4%; Score 15; DB 20; Length 22;
Best Local Similarity 100.0%; Pred. No. 19;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 6 GAACGTTGAGATGA 20
Db 8 GAACGTTGAGATGA 22

RESULT 12
```


ID	AAV80103	standard; DNA; 22 BP.
XX	AAV80103	
AC	AAV80103;	
DT	12-MAR-1999	(first entry)
XX		
DE	Immunomodulatory oligo comprising an ISS sequence.	
KW	Immunomodulatory; immunostimulatory; octanucleotide; immune regulation; ISS: cancer; allergy; asthma; hepatitis B infection; papillomavirus; human immunodeficiency virus; influenza; herpes; M. tuberculosis; ss; B. pertussis; malaria; plasmodia; Leishmania; Trypanosoma; Schistosoma.	
XX		
OS	Synthetic;	
XX		
FH	Key	Location/Qualifiers
FT	modified_base	11
FT		/tag= a
FT		/note= "5-bromocytosine"
XX		
PN	W09855495-A2.	
PD	10-DEC-1998.	
XX		
PF	05-JUN-1998;	98WO-US11578.
XX		
PR	06-JUN-1997;	97US-0048793.
XX		
PA	(DYNA-) DYNAX TECHNOLOGIES CORP.	
XX		
PI	Dina D. Roman M. Schwartz D;	
XX		
DR	WPI; 1999-053898/05.	
XX		
PT	Immunostimulatory oligonucleotides regulate the immune system - and contain an immune-stimulating octanucleotide sequence; for treating cancer, allergic and infectious diseases	
XX		
PS	Claim 24; Page 30; 63pp; English.	
XX		
CC	The invention relates to immunomodulatory oligonucleotides that comprise at least 1 immunostimulatory octanucleotide sequence (ISS) where the ISS sequences are selected from the group consisting of AACGTTCC, AACGTTGC, GAGGTTCC, and GAGGTTCG. The immunomodulatory sequences are used to treat patients needing immune regulation, such as those suffering from cancer, an allergic disease and asthma. They are also used to prevent infectious diseases such as influenza, herpes, hepatitis B, human immunodeficiency and papillomavirus, Hemophilus influenza, Mycobacterium tuberculosis and Bordecella pertussis, malarial plasmodia, Leishmania, Trypanosoma and Schistosoma. The immunomodulatory sequences are used to screen for human immunostimulatory activity by incubating macrophage cells and the oligonucleotide; and determining the relative amount of Th1-biased cytokines in the supernatant. Sequences AAV80096 to AAV80103 represent specific claimed examples of such immunomodulatory oligonucleotides.	
XX		
XX	Sequence 22 BP; 6 A; 3 C; 7 G; 6 T; 0 other;	
XX		
XX	Query Match	71.4%; Score 15; DB 20; Length 22;
XX	Best Local Similarity	100.0%; Pred. No. 19;
XX	Matches 15; Conservative	0; Mismatches 0; Indels 0; Gaps 0
QY	6 GAACGTTGAGATGA 20	
DB	8 GACGTTGAGATGA 22	
XX		
XX	RESULT 13	
XX	ID AAV80103	
XX	AAV80103	
XX	AAV80103 standard; DNA; 22 BP.	
XX	AAV80103	

[illegible]

KW Antitumour; immunostimulatory oligonucleotide; tumour; anaplasia;
 KW glioblastoma; medullablastoma; neuroblastoma; melanoma; carcinoma; ss.
 XX Synthetic.
 XX WO200056342-A2.
 XX 28-SEP-2000.
 PD 17-MAR-2000; 2000WO-FR00676.
 PF 19-MAR-1999; 99FR-0003433.
 XX (ASSI-) ASSISTANCE PUBLIQUE HOPITAUX PARIS.
 PA (INRM) INST NAT SANTE & RECH MEDICALE.
 PI Carpentier A;
 XX WPI; 2000-602192/57.
 DR WPI; 2000-602192/57.
 XX Use of stabilised oligonucleotides as antitumor agents, particularly
 PT against nervous system tumors, have optimal activity and are not toxic
 PT -
 XX Example 2; Page 16; 57pp; French.
 PS The present sequence represents a stabilised oligonucleotide which has
 CC antitumour activity. The oligonucleotide comprises an octamer motif
 CC of the type 5'-purine-purine-CG-pyrimidine-pyrimidine-X-X-3', where
 CC the pair X-X is AT, AA, CT or TT. The oligonucleotides are
 CC immunostimulatory, and are not toxic. They may be adapted for use in
 CC animals or humans. The stabilised oligonucleotides are used for
 CC treating tumours, of any type and any degree of anaplasia, particularly
 CC human tumours in the peripheral or central nervous systems, specifically
 CC glioblastomas, medullablastomas, neuroblastomas, melanomas or carcinomas.
 XX SQ Sequence 22 BP; 6 A; 3 C; 7 G; 6 T; 0 other;
 QY Query Match 71.4%; Score 15; DB 21; Length 22;
 Db Best Local Similarity 100.0%; Pred. No. 19;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 6 GAACGTCGAGATGA 20
 Db 8 GAACGTCGAGATGA 22
 RESULT 15
 AAA90458
 ID AAA90458 standard; DNA; 22 BP.
 AC AAA90458;
 XX 10-JAN-2001 (first entry)
 DT 10-JAN-2001 (first entry)
 XX CPG adjuvant oligonucleotide, SEQ ID NO:19.
 DE CPG oligonucleotide; CPG motif; adjuvant; microdroplet emulsion;
 KW microemulsion; adsorbent microparticle; vaccine; Th1 immune response;
 KW viral infection; bacterial infection; parasitic infection; HCV; HBV;
 KW hepatitis C virus; hepatitis B virus; herpes simplex virus; HSV; HIV;
 KW human immunodeficiency virus; cytomegalovirus; CMV; influenza virus;
 KW rabies virus; cholera; diphtheria; tetanus; pertussis;
 KW Helicobacter pylori; Haemophilus influenzae; malaria; ss.
 XX Synthetic.
 OS Synthetic.
 PN WO200050006-A2.
 XX 31-AUG-2000.
 PD 31-AUG-2000.
 XX 09-FEB-2000; 2000WO-US0331.
 PF 09-FEB-2000; 2000WO-US0331.
 XX

PR 26-FEB-1999; 99US-0121858.
 PR 28-JUL-1999; 99US-0146391.
 PR 28-OCT-1999; 99US-0161997.
 XX (CHIR) CHIRON CORP.
 PA O'Hagan D, Ott GS, Donnelly J, Kazaz J, Ugozzoli M, Singh M;
 PI Barackman J;
 XX WPI; 2000-587123/55.
 DR WPI; 2000-587123/55.
 XX Microemulsion having an adsorbent surface comprising a microdroplet
 PT emulsion consisting of a metabolizable oil and an emulsifying agent
 PT which is a detergent, useful as a vaccine to treat bacterial, viral,
 PT and parasitic infection -
 XX Claim 17; Page 40; 95pp; English.
 PS The invention relates to a microdroplet emulsion (microemulsion) with an
 CC adsorbent surface, and which comprises a metabolizable oil and an
 CC emulsifying agent (a detergent). It also relates to a composition
 CC comprising the microemulsion and a microparticle with an adsorbent
 CC surface, where the microparticle comprises a polymer selected from a
 CC poly(alpha-hydroxy acid), a polyhydroxy butyric acid, a
 CC polycaprolactone, a polyorthoester, a polyhydride, and a
 CC polycyanacrylate, and a second detergent. The surface of the
 CC microparticles efficiently adsorb biologically active macromolecules such
 CC as DNA, polypeptides, antigens, hormones, pharmaceuticals, enzymes,
 CC mediators of transcription or translation, metabolic intermediates and
 CC adjuvants. Additionally, a second biologically active molecule may be
 CC encapsulated within the microparticle. The microemulsion can be used in
 CC methods of immunising a host animal, particularly a human, against a
 CC viral, bacterial or parasitic infection, and in methods of increasing a
 CC Th1 immune response. The microemulsions (having the appropriate antigens
 CC adsorbed) may be particularly used as vaccines for hepatitis C virus
 CC (HCV), hepatitis B virus (HBV), herpes simplex virus (HSV), human
 CC immunodeficiency virus (HIV), cytomegalovirus (CMV), influenza virus, and
 CC rabies virus; the bacteria which cause cholera, diphtheria, tetanus and
 CC pertussis; Helicobacter pylori and Haemophilus influenzae; and
 CC malaria-causing parasites. Sequences AAA90447-A90467 represent Th1
 CC lymphocyte stimulating oligonucleotides containing at least one CPG motif
 CC which are claimed for use as adjuvants in the compositions of the
 CC invention.
 CC XX SQ Sequence 22 BP; 6 A; 3 C; 7 G; 6 T; 0 other;
 QY Query Match 71.4%; Score 15; DB 21; Length 22;
 Db Best Local Similarity 100.0%; Pred. No. 19;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 6 GAACGTCGAGATGA 20
 Db 8 GAACGTCGAGATGA 22

Search completed: December 19, 2003, 13:45:58
 Job time : 149 secs



Creation date: 05-25-2005
Indexing Officer: ZPETROS - ZENEBECH PETROS
Team: OIPEBackFileIndexing
Dossier: 10185057

Legal Date: 06-07-2004

No.	Doccode	Number of pages
1	SRNT	330

Total number of pages: 330

Remarks:

Order of re-scan issued on

